JP2009114082A - Hair papilla cell proliferation promoter, fibroblast growth factor-7 (fgf-7) production promoter, vascular endothelial growth factor (vegf) production promoter, antiandrogenic agent, hair grower and hair cosmetic - Google Patents
Hair papilla cell proliferation promoter, fibroblast growth factor-7 (fgf-7) production promoter, vascular endothelial growth factor (vegf) production promoter, antiandrogenic agent, hair grower and hair cosmetic Download PDFInfo
- Publication number
- JP2009114082A JP2009114082A JP2007285821A JP2007285821A JP2009114082A JP 2009114082 A JP2009114082 A JP 2009114082A JP 2007285821 A JP2007285821 A JP 2007285821A JP 2007285821 A JP2007285821 A JP 2007285821A JP 2009114082 A JP2009114082 A JP 2009114082A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- hair
- production
- promoter
- gold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 96
- 210000004209 hair Anatomy 0.000 title claims abstract description 85
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title claims abstract description 61
- 239000000051 antiandrogen Substances 0.000 title claims abstract description 26
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 229940098448 fibroblast growth factor 7 Drugs 0.000 title claims description 59
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title claims description 44
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims description 42
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims description 41
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title description 37
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150095289 FGF7 gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 142
- 239000004480 active ingredient Substances 0.000 claims abstract description 33
- 230000010261 cell growth Effects 0.000 claims abstract description 14
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 58
- 210000004709 eyebrow Anatomy 0.000 claims description 46
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 46
- 239000010931 gold Substances 0.000 claims description 46
- 229910052737 gold Inorganic materials 0.000 claims description 46
- 230000002401 inhibitory effect Effects 0.000 claims description 46
- 210000000078 claw Anatomy 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 102000001307 androgen receptors Human genes 0.000 claims description 28
- 108010080146 androgen receptors Proteins 0.000 claims description 28
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 claims description 27
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 claims description 27
- 230000002280 anti-androgenic effect Effects 0.000 claims description 27
- 241000196324 Embryophyta Species 0.000 abstract description 54
- 230000006711 vascular endothelial growth factor production Effects 0.000 abstract description 31
- 244000206184 Polygala chinensis Species 0.000 abstract description 9
- 241000735332 Gerbera Species 0.000 abstract description 6
- 239000007952 growth promoter Substances 0.000 abstract description 6
- 241001638289 Polygala japonica Species 0.000 abstract description 5
- 244000171168 Desmos chinensis Species 0.000 abstract description 4
- 244000002639 Delonix regia Species 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 87
- 230000001737 promoting effect Effects 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- 230000009471 action Effects 0.000 description 41
- 238000000605 extraction Methods 0.000 description 39
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 38
- 239000000523 sample Substances 0.000 description 31
- 230000002500 effect on skin Effects 0.000 description 25
- 239000002904 solvent Substances 0.000 description 23
- 230000003779 hair growth Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 229940088597 hormone Drugs 0.000 description 19
- 239000005556 hormone Substances 0.000 description 19
- 229960003604 testosterone Drugs 0.000 description 19
- 239000002609 medium Substances 0.000 description 17
- 244000025254 Cannabis sativa Species 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 201000004384 Alopecia Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000000469 ethanolic extract Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- CBMYJHIOYJEBSB-KHOSGYARSA-N 5alpha-androstane-3alpha,17beta-diol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-KHOSGYARSA-N 0.000 description 8
- 244000305267 Quercus macrolepis Species 0.000 description 8
- -1 aliphatic alcohols Chemical class 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- 239000003676 hair preparation Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 7
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 7
- 239000003098 androgen Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 229940126864 fibroblast growth factor Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000003780 hair follicle Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 235000011511 Diospyros Nutrition 0.000 description 5
- 244000236655 Diospyros kaki Species 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 239000003240 coconut oil Substances 0.000 description 5
- 235000019864 coconut oil Nutrition 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000031774 hair cycle Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 244000295724 Allium chinense Species 0.000 description 4
- 235000016790 Allium chinense Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000012264 purified product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001249608 Delonix Species 0.000 description 2
- 241000926826 Desmos cochinchinensis Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001046 green dye Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000002488 outer root sheath cell Anatomy 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000871539 Choerospondias Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 241000447394 Desmos Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 244000050053 Rosa multiflora Species 0.000 description 1
- 235000000656 Rosa multiflora Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005158 Thymus praecox ssp. arcticus Nutrition 0.000 description 1
- 240000006001 Thymus serpyllum Species 0.000 description 1
- 235000004054 Thymus serpyllum Nutrition 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 235000013030 Voandzeia subterranea Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZTLBKEBOAKWETD-UHFFFAOYSA-N [Na].[N+](=O)([O-])C1=C(C(=CC=C1)OC)O Chemical compound [Na].[N+](=O)([O-])C1=C(C(=CC=C1)OC)O ZTLBKEBOAKWETD-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940069826 chlorella vulgaris extract Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 101150089047 cutA gene Proteins 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000007924 ground bean Nutrition 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000492 lymphangiogenic effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Abstract
Description
本発明は、毛乳頭細胞増殖促進剤、線維芽細胞増殖因子−７（ＦＧＦ−７）産生促進剤、血管内皮増殖因子（ＶＥＧＦ）産生促進剤、抗男性ホルモン剤、育毛剤及び頭髪化粧料に関するものである。 The present invention relates to a dermal papilla cell growth promoter, a fibroblast growth factor-7 (FGF-7) production promoter, a vascular endothelial growth factor (VEGF) production promoter, an antiandrogen, a hair restorer, and a hair cosmetic. Is.
毛髪の成長は、成長期、退行期、休止期からなる周期的なヘアサイクル（毛周期）に従って成長及び脱落を繰り返している。このヘアサイクルのうち、休止期から成長期へかけての新たな毛包が形成されるステージが、発毛に最も重要であると考えられており、このステージにおける毛包上皮系細胞の増殖・分化に重要な役割を果たしているのが、毛乳頭細胞であると考えられている。毛乳頭細胞は、毛根近傍にある外毛根鞘細胞とマトリックス細胞とからなる毛包上皮系細胞の内側にあって、基底膜に包まれている毛根の根幹部分に位置する細胞であり、毛包上皮系細胞へ働きかけてその増殖を促す等、毛髪への分化に重要な役割を担っている（非特許文献１参照）。 Hair growth repeats growth and loss according to a periodic hair cycle (hair cycle) consisting of a growth period, a regression period, and a rest period. Of these hair cycles, the stage at which new hair follicles are formed from the resting stage to the growing stage is considered to be the most important for hair growth. It is thought that hair papilla cells play an important role in differentiation. The dermal papilla cell is a cell located inside the hair follicle epithelial cell composed of outer root sheath cells and matrix cells in the vicinity of the hair root, and located in the root portion of the hair root wrapped in the basement membrane. It plays an important role in differentiation into hair, such as by acting on epithelial cells to promote their proliferation (see Non-Patent Document 1).
このように、毛乳頭細胞は、毛包上皮系細胞の増殖・分化および毛髪の形成において最も重要な役割を果たしており、従来、毛乳頭細胞に対象物質を接触させて、その細胞の増殖活性の有無及び／又は強弱を特定することで、その対象物質の育毛効果を検定する方法が提案されている（特許文献１参照）。また、従来、毛乳頭細胞増殖促進作用を有する生薬としては、例えば、ハトムギ抽出物、ワイルドタイム抽出物、スギナ抽出物、ショウブ抽出物、ローズマリー抽出物、ウコン抽出物、シラカバ抽出物及びコウチャ抽出物等が提案されている（特許文献２参照）。 Thus, dermal papilla cells play the most important role in the proliferation and differentiation of hair follicle epithelial cells and the formation of hair. Conventionally, the target substance is brought into contact with the dermal papilla cells, and the proliferation activity of the cells is controlled. A method for testing the hair-growth effect of the target substance by specifying the presence and / or strength is proposed (see Patent Document 1). Conventional herbal medicines having a dermal papilla cell growth promoting action include, for example, pearl barley extract, wild thyme extract, cedar extract, shobu extract, rosemary extract, turmeric extract, birch extract and kocha extract. A thing etc. are proposed (refer patent document 2).
多くのステロイドホルモンは産生臓器から分泌された分子型で受容体と結合してその作用を発現するが、アンドロゲンと総称される男性ホルモンの場合、例えばテストステロンは標的臓器の細胞内に入ってテストステロン５α−レダクターゼにより５α−ジヒドロテストステロン（５α−ＤＨＴ）に還元されてから受容体と結合し、アンドロゲンとしての作用を発現する。 Many steroid hormones are expressed in the form of molecules secreted from the production organ and bind to receptors to express their action. In the case of male hormones collectively called androgens, for example, testosterone enters the cells of the target organ and enters testosterone 5α. -It is reduced to 5α-dihydrotestosterone (5α-DHT) by reductase, and then binds to a receptor to express an action as an androgen.
アンドロゲンは重要なホルモンであるが、それが過度に作用すると、男性型禿頭、多毛症、脂漏症、座瘡、前立腺肥大症、前立腺腫瘍、男児性早熟等、さまざまな好ましくない症状を誘発する。そこで、過剰のアンドロゲンの作用を抑制することによりこれら好ましくない症状を改善する手法が検討されている。具体的には、テストステロンを活性型５α−ＤＨＴに還元するテストステロン５α−レダクターゼの作用を阻害することにより活性型５α−ＤＨＴを生じるのを抑制する方法と、テストステロンから生じた５α−ＤＨＴが受容体と結合するのを阻害することによりアンドロゲン活性を発現させない方法とが提案されている。 Androgen is an important hormone, but when it acts excessively, it induces various unfavorable symptoms such as androgenetic baldness, hirsutism, seborrhea, acne, benign prostatic hyperplasia, prostate tumor, premature boyhood, etc. . Therefore, a technique for improving these undesirable symptoms by suppressing the action of excess androgen has been studied. Specifically, a method for suppressing the production of active 5α-DHT by inhibiting the action of testosterone 5α-reductase that reduces testosterone to active 5α-DHT, and 5α-DHT produced from testosterone are receptors There has been proposed a method in which androgen activity is not expressed by inhibiting the binding to the enzyme.
前記方法が検証された結果、シプロテンアセテート、オキセンドロン、酢酸クロマジノン等の有効性が確認された。しかしながら、これらの化合物はステロイド類似構造を有しているために、ホルモン様作用等の好ましくない副作用を有するという欠点がある。従来、テストステロン５α−レダクターゼ阻害作用を有する生薬としては、例えば、Choerospondias属に属する植物（特許文献３参照）、五斂子（特許文献４参照）、紅豆杉、鳥欖、幌傘楓、穿心蓮（特許文献５参照）等が知られている。また、５α−ＤＨＴとその受容体との結合を阻害する作用を有する生薬としては、例えば、マジト、カチュア（特許文献６参照）、藤茶（特許文献７参照）等が報告されている。 As a result of the verification of the method, the effectiveness of cyproten acetate, oxendron, chromadianone acetate and the like was confirmed. However, since these compounds have a steroid-like structure, they have the disadvantage of having undesirable side effects such as hormone-like effects. Conventional herbal medicines having a testosterone 5α-reductase inhibitory action include, for example, plants belonging to the genus Choerospondias (see Patent Document 3), five lions (see Patent Document 4), red bean cedar, bird cage, horo umbrella candy, chinshin lotus ( Patent Document 5) is known. Moreover, as a crude drug which has the effect | action which inhibits the coupling | bonding of 5 (alpha) -DHT and its receptor, a majito, cuta (refer patent document 6), Fuji tea (refer patent document 7), etc. are reported, for example.
線維芽細胞増殖因子（ＦＧＦ）は線維芽細胞に対して増殖活性を有するだけでなく、様々な細胞に対する細胞増殖・分化活性を有する形態形成因子、組織障害のときに働く組織修復因子、生体の恒常性を維持するための代謝調節因子として重要な役割を果たしている多機能性分泌因子である。そのようなＦＧＦとして、例えばＦＧＦ−７がある。近年、ＦＧＦ−７について、男性型脱毛症における毛乳頭での発現低下が報告されている（非特許文献２参照）。これまで、ＦＧＦ−７の発現を促進させるものとしてアデノシンが知られているが（特許文献８参照）、植物からの抽出物にＦＧＦ−７産生促進作用のあるものはあまり知られていなかった。 Fibroblast growth factor (FGF) not only has a proliferative activity on fibroblasts, but also a morphogenic factor that has cell proliferation / differentiation activities on various cells, a tissue repair factor that works in the event of tissue damage, It is a multifunctional secretory factor that plays an important role as a metabolic regulator for maintaining homeostasis. An example of such FGF is FGF-7. In recent years, FGF-7 has been reported to have decreased expression in the hair papilla in male pattern baldness (see Non-Patent Document 2). Until now, although adenosine is known as what promotes the expression of FGF-7 (refer patent document 8), the thing which has a FGF-7 production promotion effect in the extract from a plant was not known so much.
血管内皮増殖因子（ＶＥＧＦ）は、分子量３４〜４６ｋＤａの糖蛋白質であり、血管内皮細胞に特異的な増殖因子として、脳下垂体の濾胞細胞の培養液から発見され、血管透過性因子（ＶＰＦ）と同一物質であることがわかった。下垂体細胞以外には、平滑筋細胞、マクロファージ、肺胞上皮細胞、肝細胞、毛乳頭細胞等の正常細胞で産生されるほか、グリオーマ（神経膠腫）、乳癌、胃癌、大腸癌等の多くの腫瘍細胞からも産生されることが知られている。ＶＥＧＦは、血管内皮細胞にはたらき、細胞の増殖、遊走を促進させたり、血管を新生させたりする作用がある。生体においてＶＥＧＦは、胎生期の心臓の形成時期に強く発現することが認められている。ＶＥＧＦ遺伝子が欠損すると血管系の異常が起こり、胎生期に死亡することが報告されており、ＶＥＧＦは、個体の発達、組織形成において極めて重要なはたらきを持つことが示唆されている。最近では、ＶＥＧＦファミリーの新しいメンバーであるＶＥＧＦ−Ｃが、強力なリンパ管新生因子として皮膚におけるリンパ管の成長を仲介していることが同定された。 Vascular endothelial growth factor (VEGF) is a glycoprotein having a molecular weight of 34 to 46 kDa, and is found as a growth factor specific to vascular endothelial cells from a culture solution of pituitary follicular cells. Vascular permeability factor (VPF) Was found to be the same substance. In addition to pituitary cells, they are produced by normal cells such as smooth muscle cells, macrophages, alveolar epithelial cells, hepatocytes, and dermal papilla cells, as well as gliomas (gliomas), breast cancer, stomach cancer, colon cancer, etc. It is also known to be produced from tumor cells. VEGF acts on vascular endothelial cells, and has an action of promoting cell proliferation and migration, or vascularization. In vivo, VEGF is recognized to be strongly expressed during the embryonic heart formation. It has been reported that when the VEGF gene is deficient, abnormalities of the vascular system occur and die during the embryonic period, and VEGF has been suggested to have an extremely important function in the development and tissue formation of individuals. Recently, VEGF-C, a new member of the VEGF family, has been identified as a potent lymphangiogenic factor that mediates lymphatic vessel growth in the skin.
ところで、毛包においては、外毛根鞘細胞と毛乳頭細胞とがＶＥＧＦを産生することが知られている（非特許文献３，４参照）。毛包におけるＶＥＧＦの産生阻害は、ヘアサイクルの成長期の遅れと毛包サイズの矮小化とに繋がることが見出され（非特許文献５参照）、このことから毛包の発達や再生にＶＥＧＦが重要であることが示された。これまでに、ＶＥＧＦ産生を促進させる植物エキスとして、ヒルガオ科のアサガオカラクサ属植物（特許文献９参照）、ローヤルゼリー（特許文献１０参照）、Ｌ−グルタミン酸又はその塩、Ｌ−セリン、ＰＣＡ（ピロリドンカルボン酸）又はその塩、モノニトログアヤコールナトリウム、クロレラ（Chlorella vulgaris）の抽出物、ユズ（Citrus junos）の果実の抽出物、ウンシュウミカン（Citrus unshiu）の果皮の抽出物、エイジツ（Rosa multiflora）の果実の抽出物、イチョウ（Ginkgo biloba）の葉の抽出物より選択されるもの（特許文献１１参照）等が知られている。
上述したように、安全性及び生産性に優れ、日常的に摂取可能であり、かつ安価でありながら高い毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用及びアンドロゲン受容体結合阻害作用からなる群より選ばれる１種又は２種以上の作用を有する天然系の各種製剤に対する需要者の要望は極めて高い。また、これらの作用及び効果を有する頭髪化粧料に対する需要者の要望も極めて高い。 As described above, it is excellent in safety and productivity, can be ingested on a daily basis, and is inexpensive but has a high hair papillary cell growth promoting action, FGF-7 production promoting action, VEGF production promoting action, testosterone 5α-reductase There is an extremely high demand from consumers for various natural preparations having one or more actions selected from the group consisting of an inhibitory action and an androgen receptor binding inhibitory action. In addition, the demand of consumers for hair cosmetics having these functions and effects is extremely high.
しかしながら、従来においては、これらの作用及び効果を有する具体的な有効成分が、知られていないという問題があった。また、具体的な有効成分が知られているものについても、植物由来のものでなかったり、植物由来のものであったとしてもこれらの作用及び効果が十分ではなかったりするという問題があった。なお、植物由来であると、比較的安全性が高いので、日常的に摂取しやすいという利点がある。 However, conventionally, there has been a problem that specific active ingredients having these functions and effects are not known. Moreover, about what a specific active ingredient is known, there also existed a problem that these actions and effects were not enough even if it was not derived from a plant, or was derived from a plant. In addition, since it is comparatively high in plant origin, there exists an advantage that it is easy to ingest on a daily basis.
そこで、本発明は第一に、安全性の高い天然物の中から毛乳頭細胞増殖促進作用を有するものを見出し、それを有効成分とする毛乳頭細胞増殖促進剤を提供することを目的とする。 Accordingly, the first object of the present invention is to find a hair papillary cell proliferation promoting agent from among highly safe natural products, and to provide a hair papillary cell proliferation promoting agent comprising this as an active ingredient. .
本発明は第二に、安全性の高い天然物の中から線維芽細胞増殖因子−７（ＦＧＦ−７）産生促進作用を有するものを見出し、それを有効成分とする線維芽細胞増殖促進因子−７（ＦＧＦ−７）産生促進剤を提供することを目的とする。 Secondly, the present invention finds a fibroblast growth factor-7 (FGF-7) production-promoting action among highly safe natural products, and uses it as an active ingredient fibroblast growth promoting factor- 7 (FGF-7) production promoter.
本発明は第三に、安全性の高い天然物の中から血管内皮細胞増殖因子（ＶＥＧＦ）産生促進作用を有するものを見出し、それを有効成分とする血管内皮細胞増殖因子（ＶＥＧＦ）産生促進剤を提供することを目的とする。 Third, the present invention finds a highly safe natural product having a vascular endothelial growth factor (VEGF) production promoting action, and a vascular endothelial growth factor (VEGF) production promoter containing the same as an active ingredient The purpose is to provide.
本発明は第四に、安全性の高い天然物の中からテストステロン５α−レダクターゼ阻害作用及び／又はアンドロゲン受容体結合阻害作用を有するものを見出し、それを有効成分とする抗男性ホルモン剤を提供することを目的とする。 Fourthly, the present invention finds a highly safe natural product having a testosterone 5α-reductase inhibitory action and / or an androgen receptor binding inhibitory action, and provides an anti-androgen agent containing the active ingredient as an active ingredient. For the purpose.
本発明は第五に、安全性の高い天然物の中から毛乳頭細胞増殖促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、線維芽細胞増殖因子−７（ＦＧＦ−７）産生促進作用及び血管内皮細胞増殖因子（ＶＥＧＦ）産生促進作用からなる群より選ばれる１種又は２種以上の作用を有するものを見出し、それを有効成分とする育毛剤を提供することを目的とする。 Fifth, among the highly safe natural products, the present invention is a dermal papilla cell growth promoting action, testosterone 5α-reductase inhibitory action, androgen receptor binding inhibitory action, fibroblast growth factor-7 (FGF-7) production An object of the present invention is to provide a hair restorer that has one or more kinds of actions selected from the group consisting of a promoting action and a vascular endothelial growth factor (VEGF) production promoting action, and using the same as an active ingredient. .
本発明は第六に、安全性の高い天然物の中から毛乳頭細胞増殖促進作用、線維芽細胞増殖因子−７（ＦＧＦ−７）産生促進作用、血管内皮細胞増殖因子（ＶＥＧＦ）産生促進作用、テストステロン５α−レダクターゼ阻害作用及びアンドロゲン受容体結合阻害作用からなる群より選ばれる１種又は２種以上の作用を有するものを見出し、それを配合した頭髪化粧料を提供することを目的とする。 Sixth, the present invention is based on a highly safe natural product that promotes the growth of dermal papilla cells, promotes the production of fibroblast growth factor-7 (FGF-7), and promotes the production of vascular endothelial growth factor (VEGF). An object of the present invention is to provide a hair cosmetic containing one or more selected from the group consisting of a testosterone 5α-reductase inhibitory action and an androgen receptor binding inhibitory action, and a combination thereof.
上記課題を解決するため、本発明の毛乳頭細胞増殖促進剤、抗男性ホルモン剤及び育毛剤は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有することを特徴とする。また、本発明の線維芽細胞増殖因子（ＦＧＦ−７）産生促進剤は、金不換、ヒメハギ、小花遠志及び白眉草からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有することを特徴とする。さらに、本発明の血管内皮増殖因子（ＶＥＧＦ）産生促進剤は、金不換、ヒメハギ、小花遠志、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有することを特徴とする。さらにまた、本発明の頭髪化粧料は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を配合したことを特徴とする。 In order to solve the above-mentioned problems, the hair papilla cell proliferation promoter, anti-androgen hormone agent and hair-growth agent of the present invention are one kind selected from the group consisting of gold conversion, Himehagi, Kobana Toshi, Kashiwagi, white brow grass, and false falcon nails. Or it contains the extract from 2 or more types of plants as an active ingredient, It is characterized by the above-mentioned. Moreover, the fibroblast growth factor (FGF-7) production promoter of the present invention is an active ingredient comprising an extract from one or two or more plants selected from the group consisting of gold inversion, Japanese scallion, Enshi Kobana and white-browed grass. It is characterized by containing as. Furthermore, the vascular endothelial growth factor (VEGF) production promoter of the present invention effectively uses an extract from one or two or more plants selected from the group consisting of gold inversion, himehagi, floret enshi, white eyebrows, and false hawk claws. It is contained as a component. Furthermore, the hair cosmetic composition of the present invention is formulated with an extract from one or more kinds of plants selected from the group consisting of money conversion, himehagi, kotobana oshishi, kashiwagi, white eyebrows, and falcon claws. Features.
本発明の抗男性ホルモン剤においては、上記植物からの抽出物が、テストステロン５α−レダクターゼ阻害作用を有し、上記鳳凰木からの抽出物が、アンドロゲン受容体結合阻害作用を有することが好ましい。 In the anti-androgen hormone agent of the present invention, it is preferable that the extract from the plant has a testosterone 5α-reductase inhibitory action, and the extract from the Kashiwagi has an androgen receptor binding inhibitory action.
ここで、本発明において、「アンドロゲン受容体結合阻害」とは、５α−ＤＨＴとアンドロゲン受容体との結合の阻害を意味し、その阻害様式は特に限定されるものではなく、例えば、競合的拮抗薬、非競合的拮抗薬といったアンタゴニストとしての阻害が考えられる。 Here, in the present invention, “androgen receptor binding inhibition” means inhibition of binding between 5α-DHT and androgen receptor, and the inhibition mode is not particularly limited. For example, competitive antagonism Inhibition as an antagonist such as a drug or a non-competitive antagonist is conceivable.
なお、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草又は仮鷹爪からの抽出物が、上述した作用及び効果を有することは、従来まったく知られておらず、本発明者らによる新たな知見である。 In addition, it has not been known at all that the extract from money conversion, himehagi, kotobana, kanoki, white eyebrows, or false hawk claws has the above-mentioned actions and effects, and new findings by the present inventors. It is.
本発明によれば、天然物である金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有し、安全性に優れた毛乳頭細胞増殖促進剤、線維芽細胞増殖因子（ＦＧＦ−７）産生促進剤、血管内皮増殖因子（ＶＥＧＦ）産生促進剤、抗男性ホルモン剤、育毛剤又は頭髪化粧料を提供することができる。 According to the present invention, an active ingredient contains an extract from one or more plants selected from the group consisting of a natural product, gold inversion, himehagi, floret distant, oak, white eyebrows, and falcon claws. Hair papillary cell growth promoter, fibroblast growth factor (FGF-7) production promoter, vascular endothelial growth factor (VEGF) production promoter, anti-androgen hormone agent, hair restorer or hair cosmetic Can be provided.
以下、本発明について説明する。
〔毛乳頭細胞増殖促進剤，線維芽細胞増殖因子（ＦＧＦ−７）産生促進剤，血管内皮増殖因子（ＶＥＧＦ）産生促進剤，抗男性ホルモン剤，育毛剤〕
本発明の毛乳頭細胞増殖促進剤、抗男性ホルモン剤又は育毛剤は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有する。また、本発明の線維芽細胞増殖因子（ＦＧＦ−７）産生促進剤は、金不換、ヒメハギ、小花遠志及び白眉草からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有する。さらに、本発明の血管内皮増殖因子（ＶＥＧＦ）産生促進剤は、金不換、ヒメハギ、小花遠志、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を有効成分として含有する。
The present invention will be described below.
[Hair papillary cell growth promoter, fibroblast growth factor (FGF-7) production promoter, vascular endothelial growth factor (VEGF) production promoter, anti-androgen hormone, hair restorer]
The dermal papilla cell proliferation promoter, anti-androgen hormone agent or hair-growth agent of the present invention is from one or more plants selected from the group consisting of gold inversion, himehagi, floret enshi, kashiwagi, white eyebrows and false hawk claws. Extract as an active ingredient. Moreover, the fibroblast growth factor (FGF-7) production promoter of the present invention is an active ingredient comprising an extract from one or two or more plants selected from the group consisting of gold inversion, Japanese scallion, Enshi Kobana and white-browed grass. Contained as. Furthermore, the vascular endothelial growth factor (VEGF) production promoter of the present invention effectively uses an extract from one or two or more plants selected from the group consisting of gold inversion, himehagi, floret enshi, white eyebrows, and false hawk claws. Contains as a component.
ここで、本発明において「抽出物」には、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物を抽出原料として得られる抽出液、当該抽出液の希釈液若しくは濃縮液、当該抽出液を乾燥して得られる乾燥物、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。 Here, in the present invention, the “extract” is an extract obtained by using one or two or more plants selected from the group consisting of gold inversion, Himehagi, Kobana Enshi, Kashiwagi, white eyebrows, and tentative claws as an extraction raw material. Any of liquid, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, or a roughly purified product or a purified product thereof is included.
本発明において使用する抽出原料は、金不換（キンフカン，学名：Polygala chinensis L.）、ヒメハギ（学名：Polygala japonica Houtt.）、小花遠志（ショウカオンジ，学名：Polygala arvensis Willd）、鳳凰木（ホウオウボク，学名：Delonix regina，Delonix regia）、白眉草（ハクビソウ，学名：Gerberia piloselloides Gerbera）及び仮鷹爪（カヨウソウ，学名：Desmos chinensis Lour.，Desmos cochinchinensis Lour.）からなる群より選ばれる１種又は２種以上の植物である。 The raw materials used for extraction in the present invention are gold invariant (Kinfukan, scientific name: Polygala chinensis L.), Himehagi (scientific name: Polygala japonica Houtt.), Enshi Kobana (scientific name: Polygala arvensis Willd), Kashiwagi (scientific name). ： Delonix regina, Delonix regia), White eyebrows (Hakubisou, scientific name: Gerberia piloselloides Gerbera), and falcon nail (Kayosou, scientific name: Desmos chinensis Lour., Desmos cochinchinensis Lour.) Plant.
金不換（Polygala chinensis L.）は、ヒメハギ科ヒメハギ属に属する草丈１０〜４０ｃｍの１年生草木であり、別名「大金牛草」とも呼ばれ、湖北、湖南、広東、広西等の中国各省に野生しており、これらの地域から容易に入手することができる。抽出原料として使用し得る金不換の構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、花部、地上部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは地上部である。 Money conversion (Polygala chinensis L.) is an annual plant with a plant height of 10 to 40 cm belonging to the genus Himehagi, also known as “Daikin Beef Grass”, and is wild in various provinces of China such as Hubei, Hunan, Guangdong, Guangxi And can be easily obtained from these areas. Examples of the constituent parts of the gold substitution that can be used as the extraction raw material include leaves, branches, bark, trunks, stems, fruit parts, flower parts, above-ground parts, root parts, or a mixture of these parts. Preferably, it is the above-ground part.
ヒメハギ（Polygala japonica Houtt.）は、ヒメハギ科ヒメハギ属に属する草丈１５ｃｍ程度の多年生草木であって、別名「爪子金」とも呼ばれ、東北、華北、西南等の中国各地方に分布しており、これらの地域から容易に入手することができる。抽出原料として使用し得るヒメハギの構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、花部、地上部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは地上部である。 Himehagi (Polygala japonica Houtt.) Is a perennial plant with a plant height of about 15 cm, belonging to the genus Himehagi, also known as “Nagokokin”, and is distributed in various regions of China such as Tohoku, North China, and Southwest. It can be easily obtained from these areas. Examples of the constituent parts of the Japanese butterfly that can be used as the raw material for extraction include leaves, branches, barks, trunks, stems, fruit parts, flower parts, above-ground parts, root parts, or a mixture of these parts. Preferably, it is the above-ground part.
小花遠志（Polygala avensis Willd）は、ヒメハギ科ヒメハギ属に属する草丈５〜１５ｃｍの１年生草木であり、別名「細金牛草（サイキンギュウソウ）」とも呼ばれ、江西、湖南、広東、広西等に分布しており、これらの地域から容易に入手することができる。抽出原料として使用し得る小花遠志の構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、花部、地上部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは地上部である。 Polygala avensis Willd is an annual plant of 5 to 15 cm in height belonging to the genus Himehagi, also known as “Shinkin Gyusou”, and is located in Jiangxi, Hunan, Guangdong, Guangxi, etc. It is distributed and can be easily obtained from these areas. Examples of the constituent parts of Kobana Enshi that can be used as an extraction raw material include leaves, branches, bark parts, trunks, stems, fruit parts, flower parts, above-ground parts, root parts, or a mixture of these parts. Is preferably the above-ground part.
鳳凰木（Delonix regina，Delonix regia）は、マメ科ホウオウボク属に属する１５〜２０ｍの高木であり、別名「火炎樹（カエンジュ）」とも呼ばれ、シンガポール、インドネシア、沖縄等では街路樹、緑陰樹として広く植えられており、これらの地域から容易に入手することができる。抽出原料として使用し得る鳳凰木の構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、花部、地上部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは葉部等の地上部である。 Delonix regina (Delonix regia) is a 15-20m tall tree belonging to the leguminous genus Houmoku, also known as "Kaenju". In Singapore, Indonesia, Okinawa, etc. It is widely planted and can be easily obtained from these areas. Examples of the constituent parts of an oak tree that can be used as an extraction raw material include leaf parts, branch parts, bark parts, trunk parts, stem parts, fruit parts, flower parts, above-ground parts, root parts, or a mixture of these parts. However, it is preferably a ground part such as a leaf part.
白眉草（Gerberia piloselloides Gerbera）は、キク科ガーベラ属に属する植物であり、別名「毛大丁草（モウダイテイソウ）」又は「満地香（マンチコウ）」とも呼ばれ、中国の江蘇省、淅江省、四川省、広西壮族自治区及び広東省等に分布しており、これらの地域から容易に入手することができる。抽出原料として使用し得る白眉草の構成部位としては、例えば、葉部、茎部、果実部、花部、地上部、根部、全草又はこれらの部位の混合物等が挙げられるが、好ましくは全草である。 Gerberia piloselloides Gerbera is a plant belonging to the genus Gerbera genus, also known as “Mautai Taisou” or “Manchikou”, in China's Jiangsu, Zhanjiang and Sichuan provinces. It is distributed in Guangxi and Guangdong provinces and can be easily obtained from these areas. Examples of the constituent parts of white eyebrows that can be used as an extraction raw material include leaves, stems, fruit parts, flower parts, above-ground parts, root parts, whole grasses, or a mixture of these parts. It is grass.
仮鷹爪（Desmos chinensis Lour.，Desmos cochinchinensis Lour.）は、バンレイシ科デスモス属に属する樹高３ｍ程度の低木であり、別名「酒餅葉」とも呼ばれ、海南、広東、広西等の中国各省に野生しており、これらの地域から容易に入手することができる。抽出原料として使用し得る仮鷹爪の構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、花部等の地上部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは葉部である。 Temporary claws (Desmos chinensis Lour., Desmos cochinchinensis Lour.) Is a shrub with a tree height of about 3m, belonging to the genus Desmos, and is also known as “Sake leopard leaf”, in various provinces in China such as Hainan, Guangdong and Guangxi. It is wild and can be easily obtained from these areas. Examples of the constituent parts of the false hawk nail that can be used as an extraction raw material include leaf parts, branch parts, bark parts, trunk parts, stem parts, fruit parts, flower parts and other above-ground parts, root parts, or a mixture of these parts. Although it is mentioned, Preferably it is a leaf part.
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草又は仮鷹爪からの抽出物に含有される毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用又はアンドロゲン受容体結合阻害作用を有する物質の詳細は不明であるが、植物の抽出に一般に用いられている抽出方法によって、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草又は仮鷹爪からこれらの作用を有する抽出物を得ることができる。 Hair papilla cell proliferation promoting action, FGF-7 production promoting action, VEGF production promoting action, testosterone 5α-reductase inhibitory action or Details of substances having an androgen receptor binding inhibitory effect are not clear, but these actions can be obtained from gold conversion, himehagi, floret distant radish, white brow grass, or falcon nail, depending on the extraction method commonly used for plant extraction. Can be obtained.
例えば、上記植物を乾燥した後、そのまま又は粗砕機を用いて粉砕し、抽出溶媒による抽出に供することにより、毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用又はアンドロゲン受容体結合阻害作用を有する抽出物を得ることができる。乾燥は天日で行ってもよいし、通常使用される乾燥機を使用して行ってもよい。また、ヘキサン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。脱脂等の前処理を行うことにより、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草又は仮鷹爪の極性溶媒による抽出処理を効率よく行うことができる。 For example, after drying the plant, the plant is pulverized as it is or using a crusher, and subjected to extraction with an extraction solvent, thereby promoting hair papillary cell proliferation promoting action, FGF-7 production promoting action, VEGF production promoting action, testosterone 5α- An extract having a reductase inhibitory action or an androgen receptor binding inhibitory action can be obtained. Drying may be performed in the sun or using a commonly used dryer. Moreover, after performing pretreatment, such as degreasing, with a nonpolar solvent such as hexane, it may be used as an extraction raw material. By performing pretreatment such as degreasing, extraction processing with a polar solvent such as gold inversion, Himehagi, Kobana Toshi, Kashiwagi, white eyebrow grass, or falcon nail can be performed efficiently.
抽出溶媒としては、極性溶媒を用いるのが好ましく、例えば、水、親水性有機溶媒等が挙げられ、これらを単独で又は２種以上を組み合わせて、室温又は溶媒の沸点以下の温度で使用することが好ましい。 As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water and hydrophilic organic solvents. These may be used alone or in combination of two or more at room temperature or a temperature below the boiling point of the solvent. Is preferred.
抽出溶媒として使用し得る水としては、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等のほか、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、濾過、イオン交換、浸透圧調整、緩衝化等が含まれる。したがって、本発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。 Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, and those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
抽出溶媒として使用し得る親水性有機溶媒としては、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数１〜５の低級脂肪族アルコール；アセトン、メチルエチルケトン等の低級脂肪族ケトン；１，３−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数２〜５の多価アルコール等が挙げられる。 Examples of hydrophilic organic solvents that can be used as extraction solvents include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene. Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycol, propylene glycol and glycerin.
２種以上の極性溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。例えば、水と低級脂肪族アルコールとの混合液を使用する場合には、水１０容量部に対して低級脂肪族アルコール１〜９０容量部を混合することが好ましく、水と低級脂肪族ケトンとの混合液を使用する場合には、水１０容量部に対して低級脂肪族ケトン１〜４０容量部を混合することが好ましく、水と多価アルコールとの混合液を使用する場合には、水１０容量部に対して多価アルコール１０〜９０容量部を混合することが好ましい。 When using the liquid mixture of 2 or more types of polar solvents as an extraction solvent, the mixing ratio can be adjusted suitably. For example, when using a mixed solution of water and a lower aliphatic alcohol, it is preferable to mix 1 to 90 parts by volume of a lower aliphatic alcohol with respect to 10 parts by volume of water. When using a mixed solution, it is preferable to mix 1 to 40 parts by volume of a lower aliphatic ketone with 10 parts by volume of water, and when using a mixed solution of water and a polyhydric alcohol, water 10 It is preferable to mix 10 to 90 parts by volume of a polyhydric alcohol with respect to the volume part.
抽出処理は、抽出原料に含まれる可溶性成分を抽出溶媒に溶出させ得る限り特に限定はされず、常法に従って行うことができる。例えば、抽出原料の５〜１５倍量（質量比）の抽出溶媒に、抽出原料を浸漬し、常温又は還流加熱下（約９５℃以下）で可溶性成分を抽出させた後、濾過して抽出残渣を除去することにより抽出液を得ることができる。得られた抽出液は、該抽出液の希釈液若しくは濃縮液、該抽出液の乾燥物、又はこれらの粗精製物若しくは精製物を得るために、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよい。 The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent in an amount 5 to 15 times (mass ratio) of the extraction raw material, and the soluble components are extracted at room temperature or under reflux (about 95 ° C. or lower), followed by filtration to extract the extraction residue An extract can be obtained by removing. The obtained extract is diluted, concentrated, dried, purified, etc. according to a conventional method in order to obtain a diluted or concentrated solution of the extract, a dried product of the extract, or a crude purified product or a purified product thereof. Processing may be performed.
精製は、例えば、活性炭処理、吸着樹脂処理、イオン交換樹脂処理等により行うことができる。得られた抽出液はそのままでも毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤又は育毛剤の有効成分として使用することができるが、濃縮液又は乾燥物としたものの方が使用しやすい。 Purification can be performed by, for example, activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or the like. The obtained extract can be used as an active ingredient of a hair papilla cell proliferation promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent or hair restorer as it is, but it can be used as a concentrated solution or a dried product. It is easier to use.
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草又は仮鷹爪からの抽出物は特有の匂いを有しているため、その生理活性の低下を招かない範囲で脱色、脱臭等を目的とする精製を行うことも可能であるが、頭髪化粧料に配合する場合には大量に使用するものではないから、未精製のままでも実用上支障はない。 Extracts from gold incongruent, himehagi, kobana distant, persimmon trees, white eyebrows, or falcon claws have a unique odor, so purification aimed at decolorization, deodorization, etc. within a range that does not lead to a decrease in their physiological activity However, since it is not used in a large amount when blended into hair cosmetics, there is no practical problem even if it is not purified.
以上のようにして得られる金不換、ヒメハギ、小花遠志、鳳凰木、白眉草又は仮鷹爪からの抽出物は、毛乳頭細胞増殖促進作用、抗男性ホルモン作用又は育毛作用を有しているため、それぞれの作用を利用して毛乳頭細胞増殖促進剤、抗男性ホルモン剤又は育毛剤の有効成分として用いることができる。 Since the extract from the gold inversion, Himehagi, Kobana Toshi, Kashiwagi, white eyebrows or false falcon nails obtained as described above has hair papillary cell proliferation promoting action, anti-androgenic action or hair growth action, Each action can be used as an active ingredient of a dermal papilla cell proliferation promoter, anti-androgen hormone agent or hair restorer.
また、金不換、ヒメハギ、小花遠志又は白眉草からの抽出物は、ＦＧＦ−７産生促進作用を有しているため、その作用を利用してＦＧＦ−７産生促進剤の有効成分として用いることができる。なお、ＦＧＦ−７産生促進作用を有する金不換、ヒメハギ、小花遠志又は白眉草からの抽出物は、その作用を利用してＦＧＦ−７の欠乏に起因する疾患（例えば、創傷等）の予防・治療剤の有効成分としても用いることができる。 In addition, since the extract from gold incongruent, himehagi, kotohana, or white eyebrows has an FGF-7 production promoting action, it can be used as an active ingredient of an FGF-7 production promoter by utilizing this action. . In addition, the extract from gold inversion, himehagi, kotohana, or white eyebrows having FGF-7 production promoting action can be used to prevent or treat diseases (eg, wounds) caused by FGF-7 deficiency. It can also be used as an active ingredient of an agent.
さらに、金不換、ヒメハギ、小花遠志、白眉草又は仮鷹爪からの抽出物は、ＶＥＧＦ産生促進作用を有しているため、その作用を利用してＶＥＧＦ産生促進剤の有効成分として用いることができる。なお、ＶＥＧＦ産生促進作用を有する金不換、ヒメハギ、小花遠志、白眉草又は仮鷹爪からの抽出物は、その作用を利用してＶＥＧＦの欠乏に起因する疾患（例えば、冠動脈疾患、閉塞性抹消動脈硬化症、軟骨損傷、血管形成不全、虚血性脚部疾患等）の予防・治療剤の有効成分としても用いることができる。 Furthermore, since the extract from gold incongruity, Japanese scallion, Kobana Toshi, Hakubokusa or Hakucho nail has a VEGF production promoting action, it can be used as an active ingredient of a VEGF production promoting agent using this action. . It should be noted that extracts derived from gold inversion, himehagi, floret distant, white eyebrows, or false falcon nails having a VEGF production promoting action can be used for diseases caused by VEGF deficiency (for example, coronary artery disease, obstructive peripheral artery). Sclerosis, cartilage damage, angiogenesis insufficiency, ischemic leg disease, etc.) can also be used as an active ingredient of a prophylactic / therapeutic agent.
なお、本発明においては、上記植物のうちの１種の植物からの抽出物を上記有効成分として使用してもよいし、上記植物のうちの２種以上の植物からの抽出物を混合して上記有効成分として使用してもよい。上記植物のうちの２種以上の植物からの抽出物を混合して上記有効成分として用いる場合、その配合比は、それらの作用の程度に応じて適宜決定すればよい。 In the present invention, an extract from one of the plants may be used as the active ingredient, or an extract from two or more of the plants may be mixed. You may use as said active ingredient. In the case where extracts from two or more kinds of plants among the above plants are mixed and used as the active ingredient, the blending ratio may be appropriately determined according to the degree of their action.
ここで、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する抗男性ホルモン作用は、例えば、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有するテストステロン５α−レダクターゼ阻害作用に基づいて発揮されてもよいし、鳳凰木からの抽出物が有するアンドロゲン受容体結合阻害作用に基づいて発揮されてもよいし、両作用に基づいて発揮されてもよい。ただし、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する抗男性ホルモン作用は、上記作用に基づいて発揮される抗男性ホルモン作用に限定されるものではない。なお、テストステロン５α−レダクターゼ阻害作用を有する金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物は、その作用を利用してテストステロン５α−レダクターゼ阻害剤の有効成分としても用いることができる。また、アンドロゲン受容体結合阻害作用を有する鳳凰木からの抽出物は、その作用を利用してアンドロゲン受容体結合阻害剤の有効成分としても用いることができる。 Here, the anti-androgenic action of an extract from one or more plants selected from the group consisting of gold inversion, himehagi, floret distant, oak, white eyebrows, and tentative claws is, for example, gold inversion, himehagi , May be exhibited based on the testosterone 5α-reductase inhibitory activity possessed by an extract from one or more plants selected from the group consisting of Enshi Kobana, Kashiwagi, Hakuohakusa, and Hanataka nails. It may be exhibited based on the androgen receptor binding inhibitory action of the extract from the tree, or may be exhibited based on both actions. However, the anti-androgenic action of an extract from one or more plants selected from the group consisting of gold incongruity, himehagi, floret distant, oak, white eyebrows, and tent hawk claws is demonstrated based on the above-mentioned action. It is not limited to the anti-androgenic action. In addition, the extract from one or more kinds of plants selected from the group consisting of gold inversion having a testosterone 5α-reductase inhibitory effect, Japanese scallion, Enshi Kobana, Shiroki, white eyebrows, and tentative claws uses its action. It can also be used as an active ingredient of a testosterone 5α-reductase inhibitor. In addition, an extract from Kashiwagi that has an androgen receptor binding inhibitory action can be used as an active ingredient of an androgen receptor binding inhibitor using the action.
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する育毛作用は、例えば、毛乳頭細胞増殖促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、ＦＧＦ−７産生促進作用及びＶＥＧＦ産生促進作用からなる群より選ばれる１種又は２種以上の作用に基づいて発揮される。ただし、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する育毛作用は、上記作用に基づいて発揮される育毛作用に限定されるものではない。 The hair growth action possessed by an extract from one or more plants selected from the group consisting of gold incongruity, himehagi, floret distant, oak, white eyebrows and tent hawk claws is, for example, dermal papilla cell proliferation promoting action, testosterone It is exhibited based on one or more actions selected from the group consisting of 5α-reductase inhibitory action, androgen receptor binding inhibitory action, FGF-7 production promoting action, and VEGF production promoting action. However, the hair-growth action possessed by an extract from one or more kinds of plants selected from the group consisting of gold incongruity, himehagi, floret distant sushi, persimmon trees, white eyebrows, and false hawk claws is exhibited based on the above-described action. It is not limited to the hair growth action.
本発明の毛乳頭細胞増殖促進剤、抗男性ホルモン剤又は育毛剤は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物のみからなるものであってもよいし、上記抽出物を製剤化したものであってもよい。また、本発明のＦＧＦ−７産生促進剤は、金不換、ヒメハギ、小花遠志及び白眉草からなる群より選ばれる１種又は２種以上の植物からの抽出物のみからなるものであってもよいし、上記抽出物を製剤化したものであってもよい。さらに、本発明のＶＥＧＦ産生促進剤は、金不換、ヒメハギ、小花遠志、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物のみからなるものであってもよいし、上記抽出物を製剤化したものであってもよい。 The dermal papilla cell proliferation promoter, anti-androgen hormone agent or hair-growth agent of the present invention is from one or more plants selected from the group consisting of gold inversion, himehagi, floret enshi, kashiwagi, white eyebrows and false hawk claws. It may be composed only of the above extract, or it may be a formulation of the above extract. In addition, the FGF-7 production promoter of the present invention may be composed only of an extract from one or two or more plants selected from the group consisting of gold inversion, Himehagi, Enshi Kobana, and white eyebrows. The above extract may be formulated. Furthermore, the VEGF production promoter of the present invention may consist only of an extract from one or more plants selected from the group consisting of gold inversion, himehagi, kotohana, long-browed grass, and falcon claws. Alternatively, the extract may be formulated.
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物は、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を使用して、常法に従い、粉末状、顆粒状、錠剤状、液状等の任意の剤形に製剤化することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯臭剤等を用いることができる。金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物は、他の組成物（例えば、後述する頭髪化粧料等）に配合して使用することができるほか、軟膏剤、外用液剤、貼付剤等として使用することができる。 Extracts from one or more kinds of plants selected from the group consisting of gold incongruent, himehagi, floret distant, oak, white eyebrows, and false hawk claws are pharmaceutically acceptable carriers such as dextrin, cyclodextrin, etc. Using any auxiliary, it can be formulated into an arbitrary dosage form such as powder, granule, tablet, and liquid according to a conventional method. In this case, as an auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent and the like can be used. Extracts from one or more kinds of plants selected from the group consisting of money conversion, himehagi, floret distant, persimmon tree, white eyebrows, and falcon claws are other compositions (for example, hair cosmetics described later). In addition, it can be used as an ointment, a solution for external use, a patch and the like.
なお、本発明の毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤又は育毛剤は、必要に応じて、毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、抗男性ホルモン作用又は育毛作用を有する他の天然抽出物を配合して有効成分として用いることができる。 The dermal papilla cell proliferation promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent or hair restorer of the present invention may be used to promote dermal papilla cell proliferation promotion and FGF-7 production, as necessary. Other natural extracts having an action, a VEGF production promoting action, a testosterone 5α-reductase inhibitory action, an androgen receptor binding inhibitory action, an antiandrogen action or a hair growth action can be used as an active ingredient.
本発明の毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤又は育毛剤の投与方法としては、一般に経皮投与等が挙げられるが、疾患の種類に応じて、その予防、治療等に好適な方法を適宜選択すればよい。また、本発明の毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤又は育毛剤の投与量も、疾患の種類、重症度、患者の個人差、投与方法、投与期間等によって適宜増減すればよい。 The method of administering the hair papilla cell proliferation promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent or hair restorer of the present invention generally includes transdermal administration, etc., depending on the type of disease. Thus, a suitable method for the prevention, treatment, etc. may be appropriately selected. Further, the dose of the hair papilla cell proliferation promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent or hair restorer of the present invention is also determined depending on the type, severity, individual differences of patients, and administration method. The dose may be appropriately increased or decreased depending on the administration period.
本発明の毛乳頭細胞増殖促進剤は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する毛乳頭細胞増殖促進作用を通じて、毛乳頭細胞を活性化し、毛包上皮系細胞の増殖・分化及び毛髪の形成を促進することができるとともに、毛周期において成長期から退行期及び休止期へと移行するのを防ぎ、成長期を延長させることができる。これにより、脱毛症を予防、治療又は改善することができる。本発明の毛乳頭細胞増殖促進剤が予防、治療又は改善可能な脱毛症としては、例えば、男性型脱毛症、円形脱毛症、トリコチロマニア等が挙げられる。ただし、本発明の毛乳頭細胞増殖促進剤は、これらの用途以外にも毛乳頭細胞増殖促進作用を発揮することに意義のあるすべての用途に用いることができる。 The hair papilla cell proliferation promoter of the present invention is a hair papilla cell possessed by an extract from one or two or more kinds of plants selected from the group consisting of gold inversion, himehagi, kotohana, shibuki, white eyebrows, and tentative claws. Through the growth promoting action, it can activate the dermal papilla cells, promote the proliferation and differentiation of hair follicle epithelial cells and the formation of hair, and transition from the growth phase to the regression phase and the resting phase in the hair cycle. Can prevent and prolong the growth period. Thereby, alopecia can be prevented, treated or improved. Examples of alopecia that can be prevented, treated or ameliorated by the dermal papilla cell proliferation promoter of the present invention include male pattern alopecia, alopecia areata, tricotyromania and the like. However, the dermal papilla cell proliferation promoter of the present invention can be used for all applications that are meaningful for exerting a dermal papilla cell proliferation promoting effect in addition to these applications.
本発明のＦＧＦ−７産生促進剤は、金不換、ヒメハギ、小花遠志及び白眉草からなる群より選ばれる１種又は２種以上の植物からの抽出物が有するＦＧＦ−７産生促進作用を通じて、毛乳頭細胞における線維芽細胞増殖因子−７の産生を促進し、脱毛症等を予防、治療又は改善することができるとともに、細胞全般の分化・増殖・成長因子、組織障害時に働く組織修復因子、生体の恒常性を維持するための代謝調節因子等としても利用することができる。ただし、本発明のＦＧＦ−７産生促進剤は、これらの用途以外にもＦＧＦ−７産生促進作用を発揮することに意義のあるすべての用途に用いることができる。 The FGF-7 production promoter of the present invention is a dermal papilla through a FGF-7 production promotion action possessed by an extract from one or more plants selected from the group consisting of gold inversion, himehagi, kotohana, and white eyebrows. Promotes the production of fibroblast growth factor-7 in cells and can prevent, treat or improve alopecia, etc., differentiation / proliferation / growth factors of cells in general, tissue repair factors that work in the case of tissue damage, It can also be used as a metabolic regulator for maintaining homeostasis. However, the FGF-7 production-promoting agent of the present invention can be used for all uses that are meaningful for exerting an FGF-7 production-promoting action in addition to these uses.
本発明のＶＥＧＦ産生促進剤は、金不換、ヒメハギ、小花遠志、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有するＶＥＧＦ産生促進作用を通じて、毛乳頭細胞での血管内皮増殖因子の産生を促進し、毛乳頭細胞において毛細血管を新生することができる。これにより、発毛・育毛を促進し、脱毛症等を予防、治療又は改善することができる。また、本発明のＶＥＧＦ産生促進剤は、血管内皮細胞の増殖・遊走促進因子、血管新生促進因子、血液凝固因子、血圧調節因子、皮膚におけるリンパ管の成長因子等としても利用することができる。ただし、本発明のＶＥＧＦ産生促進剤は、これらの用途以外にもＶＥＧＦ産生促進作用を発揮することに意義のあるすべての用途に用いることができる。 The VEGF production promoter of the present invention is a dermal papilla through a VEGF production promoting action possessed by an extract from one or more plants selected from the group consisting of gold inversion, himehagi, floret blossom, white eyebrows, and falcon claws. Promotes the production of vascular endothelial growth factor in cells and can recapitulate capillaries in dermal papilla cells. Thereby, hair growth and hair growth can be accelerated | stimulated and alopecia etc. can be prevented, treated, or improved. The VEGF production promoter of the present invention can also be used as a vascular endothelial cell proliferation / migration promoting factor, angiogenesis promoting factor, blood coagulation factor, blood pressure regulating factor, lymphatic growth factor in the skin, and the like. However, the VEGF production promoter of the present invention can be used for all purposes that are meaningful for exerting a VEGF production promoting action in addition to these uses.
本発明の抗男性ホルモン剤は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有するテストステロン５α−レダクターゼ阻害作用及び／又は鳳凰木からの抽出物が有するアンドロゲン受容体結合阻害作用を通じて、男性型脱毛症、多毛症、脂漏症、座瘡（ニキビ等）、前立腺肥大症、前立腺腫瘍、男児性早熟等を予防、治療又は改善することができる。ただし、本発明の抗男性ホルモン剤は、これらの用途以外にもテストステロン５α−レダクターゼ阻害作用及び／又はアンドロゲン受容体結合阻害作用を発揮することに意義のあるすべての用途に用いることができる。 The anti-androgenic hormone agent of the present invention is an inhibitor of testosterone 5α-reductase possessed by an extract from one or more kinds of plants selected from the group consisting of gold inversion, himehagi, kotobana, enoki, white-browth grass, and falcon claws. Androgen receptor binding inhibitory action of the action and / or the extract from Kashiwagi, through androgenetic alopecia, hirsutism, seborrhea, acne (acne etc.), benign prostatic hyperplasia, prostate tumor, premature male sexuality, etc. Can be prevented, treated or ameliorated. However, the anti-androgenic hormone agent of the present invention can be used for all purposes that are significant for exerting testosterone 5α-reductase inhibitory action and / or androgen receptor binding inhibitory action in addition to these uses.
本発明の育毛剤は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する毛乳頭細胞増殖促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、ＦＧＦ−７産生促進作用及びＶＥＧＦ産生促進作用からなる群より選ばれる１種又は２種以上の作用を通じて、脱毛症等を予防、治療又は改善することができ、特に男性型脱毛症の予防、治療又は改善に好適である。ただし、本発明の育毛剤は、これらの用途以外にも毛乳頭細胞増殖促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、ＦＧＦ−７産生促進作用及びＶＥＧＦ産生促進作用からなる群より選ばれる１種又は２種以上の作用を発揮することに意義のあるすべての用途に用いることができる。 The hair growth agent of the present invention has a hair papilla cell proliferation promoting action possessed by an extract from one or more plants selected from the group consisting of gold inversion, himehagi, kotohana, shiroki, white eyebrows, and false hawk claws, Prevention, treatment or improvement of alopecia through one or more actions selected from the group consisting of testosterone 5α-reductase inhibitory action, androgen receptor binding inhibitory action, FGF-7 production promoting action and VEGF production promoting action It is particularly suitable for the prevention, treatment or amelioration of male pattern baldness. However, the hair growth agent of the present invention is a group consisting of hair papillary cell proliferation promoting action, testosterone 5α-reductase inhibitory action, androgen receptor binding inhibitory action, FGF-7 production promoting action and VEGF production promoting action in addition to these uses. It can be used for all purposes that are meaningful in exerting one or more selected actions.
〔頭髪化粧料〕
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物は、毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、抗男性ホルモン作用又は育毛作用を有しており、頭髪又は頭皮に適用した場合の使用感と安全性とに優れているため、頭髪化粧料に配合するのに好適である。この場合、頭髪化粧料には、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が配合されていてもよいし、当該抽出物から製剤化した毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤又は育毛剤が配合されていてもよい。金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物、毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤又は育毛剤を頭髪化粧料に配合することによって、頭髪化粧料に毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、抗男性ホルモン作用又は育毛作用を付与することができる。
[Hair hair cosmetics]
Extracts from one or two or more plants selected from the group consisting of gold inversion, himehagi, floret distant, persimmon, white eyebrows, and false hawk claws are hair papilla cell proliferation promoting action, FGF-7 production promoting action, It has VEGF production promoting action, testosterone 5α-reductase inhibitory action, androgen receptor binding inhibitory action, anti-androgen hormone action or hair growth action, and is excellent in usability and safety when applied to the hair or scalp. Therefore, it is suitable for blending into hair cosmetics. In this case, the hair cosmetic composition may be blended with an extract from one or more plants selected from the group consisting of gold inversion, himehagi, floret ambition, persimmon, white eyebrow grass, and falcon claws. In addition, a dermal papilla cell proliferation promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent or hair restorer formulated from the extract may be blended. Extract from one or two or more kinds of plants selected from the group consisting of gold incongruent, Japanese butterfly, Kobana Toshi, Kashiwagi, white eyebrows and false falcon nails, hair papilla cell proliferation promoter, FGF-7 production promoter, VEGF By adding a production promoter, anti-androgen hormone agent or hair restorer to the hair cosmetic, the hair cosmetic promotes hair papillary cell proliferation, FGF-7 production, VEGF production, testosterone 5α-reductase inhibitor. , Androgen receptor binding inhibitory action, anti-androgen action or hair growth action can be imparted.
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を配合し得る頭髪化粧料の種類は、特に限定されるものではなく、例えば、ヘアートニック、ヘアーローション、ヘアークリーム、整髪剤、シャンプー、リンス、トリートメント等が挙げられる。 Kinds of hair cosmetics that can be blended with an extract from one or more plants selected from the group consisting of money conversion, himehagi, floret distant, oak, white eyebrows, and falcon claws are particularly limited Instead, for example, hair nick, hair lotion, hair cream, hair styling agent, shampoo, rinse, treatment and the like can be mentioned.
金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物を頭髪化粧料に配合する場合、その配合量は、頭髪化粧料の種類に応じて適宜調整することができるが、好適な配合率は、標準的な抽出物に換算して約０．０００１〜１０質量％であり、特に好適な配合率は、標準的な抽出物に換算して約０．００１〜１質量％である。 In the case where an extract from one or more plants selected from the group consisting of gold incongruent, himehagi, floret distant, oak, white eyebrows, and false talons is added to hair cosmetics, Although it can be suitably adjusted according to the type of the material, the preferred blending rate is about 0.0001 to 10% by mass in terms of a standard extract, and the particularly preferred blending rate is the standard It is about 0.001 to 1% by mass in terms of an extract.
本発明の頭髪化粧料は、金不換、ヒメハギ、小花遠志、鳳凰木、白眉草及び仮鷹爪からなる群より選ばれる１種又は２種以上の植物からの抽出物が有する毛乳頭細胞増殖促進作用、ＦＧＦ−７産生促進作用、ＶＥＧＦ産生促進作用、テストステロン５α−レダクターゼ阻害作用、アンドロゲン受容体結合阻害作用、抗男性ホルモン作用又は育毛作用を妨げない限り、通常の頭髪化粧料の製造に用いられる主剤、助剤又はその他の成分、例えば、収斂剤、殺菌・抗菌剤、美白剤、紫外線吸収剤、保湿剤、細胞賦活剤、消炎・抗アレルギー剤、抗酸化・活性酸素除去剤、油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、香料等を併用することができる。このように併用することで、より一般性のある製品となり、また、併用された上記成分との間の相乗作用が通常期待される以上の優れた効果をもたらすことがある。 The hair cosmetic composition of the present invention has a hair papillary cell proliferation promoting action possessed by an extract from one or more plants selected from the group consisting of gold inversion, himehagi, kotobana, kanoki, white eyebrows, and false hawk claws. , The main agent used in the production of normal hair cosmetics, unless it interferes with FGF-7 production promoting action, VEGF production promoting action, testosterone 5α-reductase inhibitory action, androgen receptor binding inhibitory action, anti-androgen hormone action or hair growth action , Auxiliaries or other ingredients such as astringents, bactericides / antibacterial agents, whitening agents, UV absorbers, moisturizers, cell activators, anti-inflammatory / antiallergic agents, antioxidant / active oxygen removers, fats and oils, waxes , Hydrocarbons, fatty acids, alcohols, esters, surfactants, perfumes and the like can be used in combination. By using in this way, it becomes a more general product, and a synergistic action with the above-mentioned components used in combination may bring about an excellent effect that is usually expected.
なお、本発明の毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤、育毛剤又は頭髪化粧料は、ヒトに対して好適に適用されるものであるが、それぞれの作用効果が奏される限り、ヒト以外の動物、好ましくは哺乳類動物等に対して適用することもできる。 The hair papilla cell growth promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent, hair restorer or hair cosmetic of the present invention is preferably applied to humans. As long as each effect is exhibited, it can also be applied to animals other than humans, preferably mammals.
以下、製造例、試験例及び配合例を示し、本発明を具体的に説明するが、本発明は下記の各例に何ら制限されるものではない。 Hereinafter, although a manufacture example, a test example, and a compounding example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to each following example at all.
〔製造例１〕金不換地上部抽出物の製造
金不換の地上部の粗粉砕物１００ｇに抽出溶媒１０００ｍＬを加え、穏やかに攪拌しながら８０℃にて２時間保ち、熱時濾過した。得られた抽出液を４０℃で減圧下にて濃縮し、減圧乾燥機で乾燥して金不換地上部抽出物を得た（試料１〜３）。抽出溶媒として、水、５０容量％エタノール（水とエタノールとの容量比＝１：１）、８０容量％エタノール（水とエタノールとの容量比＝１：４）を用いたときの各抽出物の収率を表１に示す。
[Production Example 1] Manufacture of gold-unconverted ground part extract To 100 g of coarsely ground product of gold-unconverted ground part, 1000 mL of extraction solvent was added, kept at 80 ° C for 2 hours with gentle stirring, and filtered while hot. The obtained extract was concentrated under reduced pressure at 40 ° C. and dried with a vacuum drier to obtain a gold-unconverted ground portion extract (Samples 1 to 3). As the extraction solvent, water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), 80% by volume ethanol (volume ratio of water to ethanol = 1: 4) The yield is shown in Table 1.
〔製造例２〕ヒメハギ地上部抽出物の製造
ヒメハギの地上部の粗粉砕物１００ｇに抽出溶媒１０００ｍＬを加え、穏やかに攪拌しながら８０℃にて２時間保ち、熱時濾過した。得られた抽出液を４０℃で減圧下にて濃縮し、減圧乾燥機で乾燥してヒメハギ地上部抽出物を得た（試料４〜６）。抽出溶媒として、水、５０容量％エタノール（水とエタノールとの容量比＝１：１）、８０容量％エタノール（水とエタノールとの容量比＝１：４）を用いたときの各抽出物の収率を表２に示す。
[Production Example 2] Production of Himehagi above-ground extract To 100 g of coarsely ground product of Himehagi, 1000 mL of extraction solvent was added, kept at 80 ° C for 2 hours with gentle stirring, and filtered while hot. The obtained extract was concentrated under reduced pressure at 40 ° C., and dried with a vacuum drier to obtain a ground bean ground extract (samples 4 to 6). As the extraction solvent, water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), 80% by volume ethanol (volume ratio of water to ethanol = 1: 4) The yield is shown in Table 2.
〔製造例３〕小花遠志地上部抽出物の製造
小花遠志の地上部の粗粉砕物１００ｇに抽出溶媒１０００ｍＬを加え、穏やかに攪拌しながら８０℃にて２時間保ち、熱時濾過した。得られた抽出液を４０℃で減圧下にて濃縮し、減圧乾燥機で乾燥して小花遠志地上部抽出物を得た（試料７〜９）。抽出溶媒として、水、５０容量％エタノール（水とエタノールとの容量比＝１：１）、８０容量％エタノール（水とエタノールとの容量比＝１：４）を用いたときの各抽出物の収率を表３に示す。
[Production Example 3] Manufacture of the above-ground extract of Enshi Kobana To 100 g of the coarsely ground product of Enshi Obana, 1000 mL of extraction solvent was added, kept at 80 ° C for 2 hours with gentle stirring, and filtered while hot. The obtained extract was concentrated under reduced pressure at 40 ° C. and dried with a vacuum dryer to obtain the above-ground extract of Kobana Enshi (Samples 7 to 9). As the extraction solvent, water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), 80% by volume ethanol (volume ratio of water to ethanol = 1: 4) The yield is shown in Table 3.
〔製造例４〕白眉草全草抽出物の製造
白眉草の全草の粗粉砕物１００ｇに抽出溶媒１０００ｍＬを加え、穏やかに攪拌しながら８０℃にて２時間保ち、熱時濾過した。得られた抽出液を４０℃で減圧下にて濃縮し、減圧乾燥機で乾燥して白眉草全草抽出物を得た（試料１０〜１２）。抽出溶媒として、水、５０容量％エタノール（水とエタノールとの容量比＝１：１）、８０容量％エタノール（水とエタノールとの容量比＝１：４）を用いたときの各抽出物の収率を表４に示す。
[Production Example 4] Production of whole white blossom grass extract To 100 g coarsely ground white blossom grass, 1000 mL of extraction solvent was added, kept at 80 ° C for 2 hours with gentle stirring, and filtered while hot. The obtained extract was concentrated under reduced pressure at 40 ° C. and dried with a vacuum drier to obtain a white eyebrow grass whole plant extract (samples 10 to 12). As the extraction solvent, water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), 80% by volume ethanol (volume ratio of water to ethanol = 1: 4) The yield is shown in Table 4.
〔製造例５〕鳳凰木葉部抽出物
鳳凰木の葉部の粗粉砕物１００ｇに抽出溶媒１０００ｍＬを加え、穏やかに攪拌しながら８０℃にて２時間保ち、熱時濾過した。得られた抽出液を４０℃で減圧下にて濃縮し、減圧乾燥機で乾燥して鳳凰木葉部抽出物を得た（試料１３〜１５）。抽出溶媒として、水、５０容量％エタノール（水とエタノールとの容量比＝１：１）、８０容量％エタノール（水とエタノールとの容量比＝１：４）を用いたときの各抽出物の収率を表５に示す。
[Production Example 5] Extract from Kashiwagi leaf 1000 mL of extraction solvent was added to 100 g of the coarsely pulverized product of Kashiwagi leaf, kept at 80 ° C. for 2 hours with gentle stirring, and filtered while hot. The obtained extract was concentrated under reduced pressure at 40 ° C. and dried with a vacuum drier to obtain Kashiwagi leaf extract (samples 13 to 15). As the extraction solvent, water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), 80% by volume ethanol (volume ratio of water to ethanol = 1: 4) The yield is shown in Table 5.
〔製造例６〕仮鷹爪葉部抽出物
仮鷹爪の葉部の粗粉砕物１００ｇに抽出溶媒１０００ｍＬを加え、穏やかに攪拌しながら８０℃にて２時間保ち、熱時濾過した。得られた抽出液を４０℃で減圧下にて濃縮し、減圧乾燥機で乾燥して仮鷹爪葉部抽出物を得た（試料１６〜１８）。抽出溶媒として、水、５０容量％エタノール（水とエタノールとの容量比＝１：１）、８０容量％エタノール（水とエタノールとの容量比＝１：４）を用いたときの各抽出物の収率を表６に示す。
[Production Example 6] Extract of falcon nail leaf part To 100 g of coarsely ground product of falcon nail leaf part, 1000 mL of extraction solvent was added, kept at 80 ° C for 2 hours with gentle stirring, and filtered while hot. The obtained extract was concentrated under reduced pressure at 40 ° C., and dried with a vacuum dryer to obtain a falcon nail leaf extract (samples 16 to 18). As the extraction solvent, water, 50% by volume ethanol (volume ratio of water to ethanol = 1: 1), 80% by volume ethanol (volume ratio of water to ethanol = 1: 4) The yield is shown in Table 6.
〔試験例１〕毛乳頭細胞増殖促進作用試験
製造例１により得られた金不換地上部抽出物（試料１〜３）、製造例２により得られたヒメハギ地上部抽出物（試料４〜６）、製造例３により得られた小花遠志地上物抽出物（試料７〜９）、製造例４により得られた白眉草全草抽出物（試料１０〜１２）、製造例５により得られた鳳凰木葉部抽出物（試料１３〜１５）及び製造例６により得られた仮鷹爪葉部抽出物（試料１６〜１８）について、以下のようにして毛乳頭細胞増殖促進作用を試験した。
[Test Example 1] Hair papilla cell proliferation promoting action test Gold-unconverted aboveground extract (samples 1 to 3) obtained in Production Example 1 and Himehagi aboveground extract (Samples 4 to 6) obtained in Production Example 2. Kobana Enshi ground extract (Samples 7 to 9) obtained by Production Example 3, White eyebrow whole plant extract obtained by Production Example 4 (Samples 10 to 12), Kashiwagi leaf part obtained by Production Example 5 About the extract (samples 13-15) and the falcon nail leaf part extract (samples 16-18) obtained by manufacture example 6, the hair papillae cell proliferation promoting effect was tested as follows.
正常ヒト頭髪毛乳頭細胞（TOYOBO社製，CA60205）を、毛乳頭細胞増殖培地（TOYOBO社製，TPGM-250）を用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を、１０％ＦＢＳ（Fetal Bovine Serum）含有ＤＭＥＭ（Dulbecco's modified minimal essential medium）培地を用いて１．０×１０４ｃｅｌｌｓ／ｍＬの細胞密度になるように希釈した後、コラーゲンコートした９６ウェルプレートに１ウェルあたり２００μＬずつ播種し、３日間培養した。培養後、培地を抜き、各試料（試料１〜１８）を無血清ＤＭＥＭに溶解した試料溶液（試料濃度は表７を参照）を各ウェルに２００μＬずつ添加し、さらに４日間培養した。 Normal human scalp hair papilla cells (TOYOBO, CA60205) were cultured using a hair papilla cell growth medium (TOYOBO, TPGM-250), and then cells were collected by trypsin treatment. The collected cells were diluted with a DMEM (Dulbecco's modified minimal essential medium) medium containing 10% FBS (Fetal Bovine Serum) to a cell density of 1.0 × 10 4 cells / mL, and then coated with collagen 96 200 μL per well was seeded on a well plate and cultured for 3 days. After culturing, the medium was removed, and 200 μL of each sample solution (samples 1 to 18) dissolved in serum-free DMEM (see Table 7 for sample concentration) was added to each well, followed by further culturing for 4 days.
毛乳頭細胞増殖促進作用は、ＭＴＴアッセイを用いて測定した。培養終了後、培地を除き、無血清ＤＭＥＭに溶解したＭＴＴ（(3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium Bromide，同仁化学研究所社製，終濃度０．４ｍｇ／ｍＬ）を、各ウェルに１００μＬずつ添加した。２時間培養した後に、細胞内に生成したブルーホルマザンを２−プロパノール１００μＬで抽出した。抽出後、波長５７０ｎｍにおける吸光度を測定した。同時に濁度として波長６５０ｎｍにおける吸光度を測定し、両者の差をもってブルーホルマザン生成量とした。なお、コントロールとして、試料溶液の代わりに無血清ＤＭＥＭを添加した場合についても同様の測定を行った。得られた結果から、下記式に基づいて、毛乳頭細胞増殖促進率（％）を算出した。 The dermal papilla cell proliferation promoting effect was measured using MTT assay. After completion of the culture, the medium was removed, and MTT dissolved in serum-free DMEM ((3- (4,5-Dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium Bromide, manufactured by Dojindo Laboratories, Inc., final concentration 0.4 mg) / ML) was added to each well in an amount of 100 μL, and after culturing for 2 hours, blue formazan produced in the cells was extracted with 100 μL of 2-propanol, and the absorbance at a wavelength of 570 nm was measured after extraction. Absorbance at a wavelength of 650 nm was measured, and the difference between the two was used as the amount of blue formazan produced.As a control, the same measurement was performed when serum-free DMEM was added instead of the sample solution. Based on the following formula, the dermal papilla cell growth promotion rate (%) was calculated.
毛乳頭細胞増殖促進率(％)＝Ａ／Ｂ×１００
式中、Ａは「試料添加時の吸光度」を表し、Ｂは「試料無添加時の吸光度」を表す。
上記試験の結果を表７に示す。
Hair papilla cell growth promotion rate (%) = A / B × 100
In the formula, A represents “absorbance when a sample is added”, and B represents “absorbance when no sample is added”.
Table 7 shows the results of the above test.
表７に示すように、金不換地上部抽出物、ヒメハギ地上部抽出物、小花遠志地上部抽出物、白眉草全草抽出物、鳳凰木葉部抽出物及び仮鷹爪葉部抽出物は、優れた毛乳頭細胞増殖促進作用を有することが確認された。また、各抽出物が有する毛乳頭細胞増殖作用は、各抽出物の濃度に依存して変化するため、毛乳頭細胞増殖促進作用の程度は、各抽出物の濃度によって調節可能であることが確認された。 As shown in Table 7, the gold-convertible above-ground extract, the ground extract, the above-ground extract of the florets, the white blossom all-weed extract, the extract of the leaves of Kashiwagi and the extract of the falcon nail are excellent. It was confirmed to have a hair papillary cell proliferation promoting action. In addition, since the hair papillary cell proliferation action of each extract changes depending on the concentration of each extract, it is confirmed that the degree of hair papillary cell proliferation promoting action can be adjusted by the concentration of each extract. It was done.
〔試験例２〕テストステロン５α−レダクターゼ阻害作用試験
製造例１により得られた金不換地上部抽出物（試料１〜３）、製造例２により得られたヒメハギ地上部抽出物（試料４〜６）、製造例３により得られた小花遠志地上物抽出物（試料７〜９）、製造例４により得られた白眉草全草抽出物（試料１０〜１２）、製造例５により得られた鳳凰木葉部抽出物（試料１３〜１５）及び製造例６により得られた仮鷹爪葉部抽出物（試料１６〜１８）について、以下のようにしてテストステロン５α−レダクターゼ阻害作用を試験した。
[Test Example 2] Testosterone 5α-reductase inhibitory action test Gold-convertible above-ground extract (Samples 1 to 3) obtained by Production Example 1, Saddle-ground above-ground extract obtained by Production Example 2 (Samples 4 to 6), Kobana Enshi ground extract (Samples 7 to 9) obtained by Production Example 3, White eyebrow whole plant extract obtained by Production Example 4 (Samples 10 to 12), Kashiwagi leaf part obtained by Production Example 5 The testosterone 5α-reductase inhibitory action was tested for the extract (samples 13 to 15) and the falcon nail extract (samples 16 to 18) obtained in Production Example 6 as follows.
蓋付Ｖ底試験管にて、プロプレングリコールで調製した４．２ｍｇ／ｍＬのテストステロン（和光純薬工業社製）２０μＬと、１ｍｇ／ｍＬのＮＡＤＰＨを含有する５ｍｍｏｌ／ｍＬのトリス塩酸緩衝液（ｐＨ７．１３）８２５μＬとを混合した。 In a V-bottom test tube with a lid, 20 μL of 4.2 mg / mL testosterone (manufactured by Wako Pure Chemical Industries, Ltd.) prepared with propylene glycol and 5 mmol / mL Tris-HCl buffer (containing 1 mg / mL NADPH) pH 7.13) 825 μL.
さらに、各試料（試料１〜１８）のエタノール水溶液８０μＬ及びＳ−９（ラット肝臓ホモジネート，オリエンタル酵母工業社製）７５μＬを加えて混合し、３７℃にて３０分間インキュベートした。その後、塩化メチレン１ｍＬを加えて反応を停止させた。これを遠心分離し（１６００×ｇ，１０分間）、塩化メチレン層を分取して、分取した塩化メチレン層について、下記の条件にてガスクロマトグラフィー分析をし、３α−アンドロスタンジオール、５α−ジヒドロテストステロン（５α−ＤＨＴ）及びテストステロンの濃度（μｇ／ｍＬ）を定量した。コントロールとして、試料溶液の代わりに試料溶媒を同量（８０μＬ）使用して同様に処理し、ガスクロマトグラフィー分析をした。 Further, 80 μL of an ethanol aqueous solution of each sample (Samples 1 to 18) and 75 μL of S-9 (rat liver homogenate, manufactured by Oriental Yeast Co., Ltd.) were added and mixed, and incubated at 37 ° C. for 30 minutes. Thereafter, 1 mL of methylene chloride was added to stop the reaction. This was centrifuged (1600 × g, 10 minutes), the methylene chloride layer was separated, and the separated methylene chloride layer was subjected to gas chromatography analysis under the following conditions to obtain 3α-androstanediol, 5α. -The concentration of dihydrotestosterone (5α-DHT) and testosterone (μg / mL) was quantified. As a control, the same amount (80 μL) of the sample solvent was used instead of the sample solution, and the same treatment was performed, and gas chromatography analysis was performed.
＜ガスクロマトグラフィー条件＞
使用装置：Shimadzu GC-7A（島津製作所社製）
カラム：ＤＢ−１７０１（内径：０．５３ｍｍ，長さ：３０ｍ，膜厚：１．０μｍ，J&W Scientific社製）
カラム温度：２４０℃
注入口温度：３００℃
検出器：ＦＩＤ
試料注入量：１μＬ
スプリット比：１：２
キャリアガス：窒素ガス
キャリアガス流速：３ｍＬ／ｍｉｎ
<Gas chromatography conditions>
Equipment used: Shimadzu GC-7A (manufactured by Shimadzu Corporation)
Column: DB-1701 (inner diameter: 0.53 mm, length: 30 m, film thickness: 1.0 μm, manufactured by J & W Scientific)
Column temperature: 240 ° C
Inlet temperature: 300 ° C
Detector: FID
Sample injection volume: 1 μL
Split ratio: 1: 2
Carrier gas: Nitrogen gas Carrier gas flow rate: 3 mL / min
３α−アンドロスタンジオール、５α−ＤＨＴ及びテストステロンの濃度の定量は、下記の方法により行った。
３α−アンドロスタンジオール、５α−ＤＨＴ及びテストステロンの標準品を塩化メチレンに溶解し、当該溶液についてガスクロマトグラフィー分析をし、これらの化合物の濃度（μｇ／ｍＬ）及びピーク面積から、ピーク面積と化合物の濃度との対応関係を予め求めておいた。そして、テストステロンとＳ−９との反応後の３α−アンドロスタンジオール、５α−ＤＨＴ及びテストステロンそれぞれのピーク面積あたりの濃度（μｇ／ｍＬ）を、予め求めておいた対応関係を利用して、下記式（１）に基づき、算出した。
Quantification of the concentrations of 3α-androstanediol, 5α-DHT and testosterone was performed by the following method.
Standard products of 3α-androstanediol, 5α-DHT and testosterone were dissolved in methylene chloride, and the solution was subjected to gas chromatography analysis. From the concentration (μg / mL) and peak area of these compounds, peak area and compound Correspondence with the concentration of was previously determined. Then, 3α-androstanediol, 5α-DHT, and testosterone after the reaction between testosterone and S-9, the concentrations per peak area (μg / mL) were calculated using the correspondence previously obtained. It calculated based on Formula (1).
Ａ＝Ｂ×Ｃ／Ｄ・・・（１）
式中、Ａは「３α−アンドロスタンジオール、５α−ＤＨＴ又はテストステロンの濃度（μｇ／ｍＬ）」を表し、Ｂは「３α−アンドロスタンジオール、５α−ＤＨＴ又はテストステロンのピーク面積」を表し、Ｃは「標準品の濃度（μｇ／ｍＬ）」を表し、Ｄは「標準品のピーク面積」を表す。
A = B × C / D (1)
In the formula, A represents “3α-androstanediol, 5α-DHT or testosterone concentration (μg / mL)”, B represents “3α-androstanediol, 5α-DHT or testosterone peak area”, and C Represents “concentration of standard product (μg / mL)”, and D represents “peak area of standard product”.
式（１）に基づいて算出された化合物濃度を使用して、下記式（２）に基づき、変換率（テストステロン５α−レダクターゼによりテストステロンが還元されて生成した３α−アンドロスタンジオール及び５α−ＤＨＴの濃度と、テストステロンの初期濃度との濃度比）を算出した。
変換率(％)＝(Ｅ＋Ｆ)／(Ｅ＋Ｆ＋Ｇ)・・・（２）
式中、Ｅは「３α−アンドロスタンジオールの濃度（μｇ／ｍＬ）」を表し、Ｆは「５α−ＤＨＴの濃度（μｇ／ｍＬ）」を表し、Ｇは「テストステロンの濃度（μｇ／ｍＬ）」を表す。
Using the compound concentration calculated based on the formula (1), based on the following formula (2), the conversion rate (of 3α-androstanediol and 5α-DHT produced by reduction of testosterone by testosterone 5α-reductase) The concentration ratio between the concentration and the initial concentration of testosterone) was calculated.
Conversion rate (%) = (E + F) / (E + F + G) (2)
In the formula, E represents “3α-androstanediol concentration (μg / mL)”, F represents “5α-DHT concentration (μg / mL)”, and G represents “testosterone concentration (μg / mL)”. ".
式（２）に基づいて算出された変換率を用いて、下記式（３）に基づき、テストステロン５α−レダクターゼ阻害率（％）を算出した。
阻害率(％)＝(１−Ｈ／Ｉ)×１００・・・（３）
式中、Ｈは「試料添加時の変換率」を表し、Ｉは「コントロールの変換率」を表す。
Using the conversion rate calculated based on the formula (2), the testosterone 5α-reductase inhibition rate (%) was calculated based on the following formula (3).
Inhibition rate (%) = (1-H / I) × 100 (3)
In the formula, H represents “conversion rate at the time of sample addition”, and I represents “control conversion rate”.
試料濃度を段階的に減少させて上記阻害率の測定を行い、テストステロン５α−レダクターゼの阻害率が５０％になる試料濃度ＩＣ５０（μｇ／ｍＬ）を内挿法により求めた。
上記試験の結果を表８に示す。
The inhibition rate was measured by gradually reducing the sample concentration, and the sample concentration IC 50 (μg / mL) at which the inhibition rate of testosterone 5α-reductase was 50% was determined by interpolation.
The results of the above test are shown in Table 8.
表８に示すように、金不換地上部抽出物、ヒメハギ地上部抽出物、小花遠志地上部抽出物、白眉草全草抽出物、鳳凰木葉部抽出物及び仮鷹爪葉部抽出物は、優れたテストステロン５α−レダクターゼ阻害作用を有することが確認された。また、テストステロン５α−レダクターゼ阻害作用の程度は、各抽出物の濃度によって調節できることが確認された。 As shown in Table 8, the gold-convertible above-ground extract, the ground extract, the above-ground extract of the small flower, the whole extract of white blossom grass, the extract of the leaves of Kashiwagi, and the extract of the falcon nail are excellent. It was confirmed to have testosterone 5α-reductase inhibitory action. It was also confirmed that the degree of testosterone 5α-reductase inhibitory action can be adjusted by the concentration of each extract.
〔試験例３〕アンドロゲン受容体結合阻害作用
製造例５により得られた鳳凰木葉部抽出物（試料１３〜１５）について、以下のようにしてアンドロゲン受容体結合阻害作用を試験した。
[Test Example 3] Androgen receptor binding inhibitory action The Kashiwagi leaf extract (samples 13 to 15) obtained in Production Example 5 was tested for androgen receptor binding inhibitory action as follows.
マウス自然発生乳がん（シオノギ癌，ＳＣ−１１５）よりクローニングされたＳＣ−３細胞を、２％ＤＣＣ−ＦＢＳ及び１０−８ｍｏｌ／Ｌテストステロンを含有するＭＥＭ培地（ＭＥＭ−２培地）を用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を１．０×１０５ｃｅｌｌｓ／ｍＬの細胞密度になるように２％ＤＣＣ−ＦＢＳ含有ＭＥＭ培地で希釈し、９６ウェルプレートに１ウェルあたり１００μＬずつ播種し、一晩培養した。 SC-3 cells cloned from mouse spontaneous breast cancer (Shionogi cancer, SC-115) are cultured using MEM medium (MEM-2 medium) containing 2% DCC-FBS and 10-8 mol / L testosterone. Thereafter, the cells were collected by trypsin treatment. The collected cells were diluted with 2% DCC-FBS-containing MEM medium to a cell density of 1.0 × 10 5 cells / mL, seeded at 100 μL per well in a 96-well plate, and cultured overnight.
培養終了後、培地を抜き、１０−９ｍｏｌ／ＬのＤＨＴを含む０．５％ＢＳＡ含有ＨａｍＦ１２＋ＭＥＭ培地（ＨＭＢ培地）に溶解した試料（試料１３〜１５，試料濃度；５０μｇ／ｍＬ）を１００μＬ添加し、４８時間培養した。その後、終濃度０．４ｇ／ｍＬでテストステロンを含有しないＭＥＭ−２培地に溶解したＭＴＴを各ウェルに１００μＬ添加した。２時間培養した後に、細胞内に生成したブルーホルマザンを２−プロパノール２００μＬで抽出した。抽出したブルーホルマザンを含有する２−プロパノールについて、ブルーホルマザンの吸収極大点がある５７０ｎｍの吸光度を測定した。 After completion of the culture, the medium was removed, and 100 μL of a sample (samples 13 to 15, sample concentration; 50 μg / mL) dissolved in 0.5% BSA-containing HamF12 + MEM medium (HMB medium) containing 10 −9 mol / L DHT was added. And cultured for 48 hours. Thereafter, 100 μL of MTT dissolved in MEM-2 medium not containing testosterone at a final concentration of 0.4 g / mL was added to each well. After culturing for 2 hours, blue formazan produced in the cells was extracted with 200 μL of 2-propanol. About 2-propanol containing the extracted blue formazan, the light absorbency of 570 nm with the absorption maximum point of a blue formazan was measured.
なお、付着細胞の影響を補正するため、同時に６５０ｎｍの吸光度も測定し、両吸光度の差をもってブルーホルマザンの生成量に比例する値とした（下記アンドロゲン受容体結合阻害率の計算式における吸光度は、この補正済み吸光度である）。 In order to correct the influence of adherent cells, the absorbance at 650 nm was also measured at the same time, and the difference between the two absorbances was taken as a value proportional to the amount of blue formazan produced (the absorbance in the calculation formula for the androgen receptor binding inhibition rate below is This is the corrected absorbance).
上記と並行して、試料単独でＳＣ−３細胞に及ぼす影響をみるため、ＨＭＢ培地にＤＨＴを添加せず試料のみを添加して、同様の培養と測定を行った。さらに、コントロールとして、試料及びＤＨＴを添加しないＨＭＢ培地で培養した場合、及び試料を添加せず１０−９ｍｏｌ／ＬのＤＨＴのみを添加したＨＭＢ培地で培養した場合についても同様の測定を行った。得られた結果から、下記式に基づいて、アンドロゲン受容体結合阻害率（％）を算出した。 In parallel with the above, in order to examine the effect of the sample alone on the SC-3 cells, the same culture and measurement were performed by adding only the sample without adding DHT to the HMB medium. Further, as a control, the same measurement was performed when culturing in a HMB medium without addition of a sample and DHT, and when culturing in a HMB medium without addition of a sample and containing only 10 −9 mol / L DHT. . From the obtained results, the androgen receptor binding inhibition rate (%) was calculated based on the following formula.
アンドロゲン受容体結合阻害率(％)＝{１−(Ｃ−Ｄ)／(Ａ−Ｂ)}×１００
式中、Ａは「ＤＨＴ添加・試料無添加の場合の吸光度」を表し、Ｂは「ＤＨＴ無添加・試料無添加の場合の吸光度」を表し、Ｃは「ＤＨＴ添加・試料添加の場合の吸光度」を表し、Ｄは「ＤＨＴ無添加・試料添加の場合の吸光度」を表す。
上記試験の結果を表９に示す
Androgen receptor binding inhibition rate (%) = {1− (C−D) / (A−B)} × 100
In the formula, A represents “absorbance when DHT is added / sample is not added”, B is “absorbance when DHT is not added / sample is not added”, and C is “absorbance when DHT is added / sample is not added”. D represents “absorbance when DHT is not added / sample is added”.
The results of the above test are shown in Table 9.
表９に示すように、鳳凰木葉部抽出物は、優れたアンドロゲン受容体結合阻害作用を有することが確認された。 As shown in Table 9, it was confirmed that the Kashiwagi leaf extract has an excellent androgen receptor binding inhibitory action.
〔試験例４〕線維芽細胞増殖因子−７（ＦＧＦ−７）及び血管内皮細胞増殖因子（ＶＥＧＦ）ｍＲＮＡ発現促進作用試験
製造例１により得られた金不換地上部５０容量％エタノール抽出物（試料２）、製造例２により得られたヒメハギ地上部５０容量％エタノール抽出物（試料５）、製造例３により得られた小花遠志地上物５０容量％エタノール抽出物（試料８）、製造例４により得られた白眉草全草５０容量％エタノール抽出物（試料１１）及び製造例６により得られた仮鷹爪葉部５０容量％エタノール抽出物（試料１７）について、以下のようにして線維芽細胞増殖因子−７（ＦＧＦ−７）及び血管内皮細胞増殖因子（ＶＥＧＦ）ｍＲＮＡ発現促進作用を試験した。なお、線維芽細胞増殖因子−７（ＦＧＦ−７）産生促進作用及び血管内皮細胞増殖因子（ＶＥＧＦ）産生促進作用の評価は、ｍＲＮＡの発現を評価することによって行った。
Test Example 4 Fibroblast Growth Factor-7 (FGF-7) and Vascular Endothelial Cell Growth Factor (VEGF) mRNA Expression Promoting Action Test Gold-unconverted above ground 50 volume% ethanol extract (Sample 2) obtained in Production Example 1 ), A 50 volume% ethanol extract above ground part obtained in Production Example 2 (sample 5), a 50 volume% ethanol extract from Enshi Kobana ground obtained in Production Example 3 (Sample 8), and obtained in Production Example 4 About the 50% by volume ethanol extract (sample 11) of the whole white eyebrows and the 50% by volume ethanol extract (sample 17) obtained from Production Example 6, the fibroblast proliferation was as follows. Factor-7 (FGF-7) and vascular endothelial growth factor (VEGF) mRNA expression promoting effects were tested. Evaluation of the fibroblast growth factor-7 (FGF-7) production promoting action and the vascular endothelial growth factor (VEGF) production promoting action was performed by evaluating the expression of mRNA.
（１）一本鎖ＤＮＡの調製
正常ヒト頭髪毛乳頭細胞（TOYOBO社製，CA60205）を、毛乳頭細胞増殖培地（TOYOBO社製，TPGM-250）を用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を２×１０５個／ｍＬの細胞密度になるように１０％ＦＢＳ含有ＤＭＥＭ培地で希釈した後、直径６０ｍｍシャーレに５ｍＬずつ播種し、一晩培養した。
(1) Preparation of single-stranded DNA Normal human hair hair papilla cells (TOYOBO, CA60205) were cultured using hair papilla cell growth medium (TOYOBO, TPGM-250), and then the cells were treated with trypsin. It was collected. The collected cells were diluted with 10% FBS-containing DMEM medium to a cell density of 2 × 10 5 cells / mL, then seeded in 5 mL portions in a 60 mm diameter petri dish, and cultured overnight.
培養終了後、試料を添加した無血清ＤＭＥＭ培地に交換し６時間培養した後、細胞を１ｍＬのＲＮＡ抽出用試薬（ISOGEN，株式会社ニッポンジーン社製）で溶解し、クロロホルムを２００μＬ添加後、遠心（１２０００回転、４℃、１５分間）にて上層ＲＮＡ層を単離し、さらにイソプロパノールで濃縮した。濃縮沈殿させた総ＲＮＡをＴＥ溶液（１０ｍＭのＴｒｉｓ−ＨＣｌ／１ｍＭのＥＤＴＡ，ｐＨ８．０）に溶解して総ＲＮＡ標品とし、ＰＣＲ装置（TaKaRa PCR Themal Cycler MP，タカラバイオ社製）及びリアルタイムＰＣＲキット（TaKaRa ExScript RT reagent Kit，RR035A，タカラバイオ社製）を用いて、ＦＧＦ−７及びＶＥＧＦｍＲＮＡ発現量を測定するための鋳型に使用する一本鎖ＤＮＡを合成した。 After completion of the culture, the medium was replaced with a serum-free DMEM medium to which a sample was added, and cultured for 6 hours. The cells were then lysed with 1 mL of RNA extraction reagent (ISOGEN, Nippon Gene Co., Ltd.), and 200 μL of chloroform was added, followed by centrifugation ( The upper RNA layer was isolated at 12,000 rpm at 4 ° C. for 15 minutes, and further concentrated with isopropanol. Concentrated and precipitated total RNA is dissolved in TE solution (10 mM Tris-HCl / 1 mM EDTA, pH 8.0) to obtain a total RNA preparation, PCR apparatus (TaKaRa PCR Themal Cycler MP, manufactured by Takara Bio Inc.) and real time Using a PCR kit (TaKaRa ExScript RT reagent Kit, RR035A, manufactured by Takara Bio Inc.), single-stranded DNA used as a template for measuring the expression levels of FGF-7 and VEGF mRNA was synthesized.
（２）サイバーグリーン法を用いたリアルタイム−ＰＣＲ反応
ＦＧＦ−７遺伝子増幅用プライマーとして下記の配列を有するセンスプライマー及びアンチセンスプライマーを作製した（タカラバイオ社製）。
センスプライマー：5'-tctgtcgaacacagtggtacctgag-3'
アンチセンスプライマー：5'-gccactgtcctgatttccatga-3'
(2) Real-time-PCR reaction using the cyber green method As a primer for FGF-7 gene amplification, a sense primer and an antisense primer having the following sequences were prepared (manufactured by Takara Bio Inc.).
Sense primer: 5'-tctgtcgaacacagtggtacctgag-3 '
Antisense primer: 5'-gccactgtcctgatttccatga-3 '
ＶＥＧＦ遺伝子増幅用プライマーとして下記の配列を有するセンスプライマー及びアンチセンスプライマーを作製した（タカラバイオ社製）。
センスプライマー：5'-gagccttgccttgctgctctac-3'
アンチセンスプライマー：5'-caccagggtctcgattggatg-3'
A sense primer and an antisense primer having the following sequences were prepared as primers for VEGF gene amplification (manufactured by Takara Bio Inc.).
Sense primer: 5'-gagccttgccttgctgctctac-3 '
Antisense primer: 5'-caccagggtctcgattggatg-3 '
また、内部標準としてのＧ３ＰＤＨ遺伝子増幅用プライマーとして下記の配列を有するセンスプライマー及びアンチセンスプライマーを作製した（タカラバイオ社製）。
センスプライマー：5'-gcaccgtcaaggctgagaac-3'
アンチセンスプライマー：5'-atggtggtgaagacgccagt-3'
Moreover, the sense primer and antisense primer which have the following arrangement | sequence were produced as a G3PDH gene amplification primer as an internal standard (made by Takara Bio Inc.).
Sense primer: 5'-gcaccgtcaaggctgagaac-3 '
Antisense primer: 5'-atggtggtgaagacgccagt-3 '
「試料無添加」、「試料添加」でそれぞれ培養した細胞から調製した総ＲＮＡ標品を基に調製した一本鎖ＤＮＡ及び検量線作成用一本鎖ＤＮＡ溶液を用いて、リアルタイムＰＣＲ装置（Real Time PCR System Smart Cycler II，Cepheid社製）及びリアルタイムＰＣＲキット（SYBR Premix Ex TaqTM，RR041A，タカラバイオ社製）でリアルタイムＰＣＲ反応を行った。なお、検量線作成用一本鎖ＤＮＡ溶液は、原液濃度の相対値を便宜的に「１００００」とし、以降５倍希釈を繰り返して濃度値「２０００」、「４００」、「８０」及び「１６」の５段階の希釈系列とした。反応は、９５℃で１０秒間保温の後、９５℃で５秒間、６０℃で２０秒間の反応を４５サイクル繰り返し、１サイクルごとにサイバーグリーン色素の発光量を測定した。 Using a single-stranded DNA prepared based on a total RNA preparation prepared from cells cultured in “sample-free” and “sample-added”, respectively, and a single-stranded DNA solution for preparing a calibration curve, a real-time PCR apparatus (Real Real-time PCR reaction was performed using Time PCR System Smart Cycler II (Cepheid) and real-time PCR kit (SYBR Premix Ex Taq ™ , RR041A, Takara Bio). In the single-stranded DNA solution for preparing a calibration curve, the relative value of the stock solution concentration is set to “10000” for convenience, and thereafter the concentration values “2000”, “400”, “80” and “16” are repeatedly diluted 5 times. "5-level dilution series". The reaction was held at 95 ° C. for 10 seconds, followed by 45 cycles of 95 ° C. for 5 seconds and 60 ° C. for 20 seconds, and the amount of luminescence of the cyber green dye was measured for each cycle.
（３）解析
各サイクルのサイバーグリーン色素の発光量からＦＧＦ−７、ＶＥＧＦ及びＧ３ＰＤＨのそれぞれをコードするＤＮＡ断片の増幅曲線を作成した。検量線作成用一本鎖ＤＮＡ溶液の希釈系列の増幅曲線から横軸に濃度、縦軸に増幅曲線の２次導関数が最大となるサイクル数をとった検量線を作成した。各発現定量用サンプルについては増幅曲線の２次導関数が最大となるサイクル数を検量線上にプロットし、相対的な発現量を算出した。ＦＧＦ−７及びＶＥＧＦ発現量は、同一サンプルにおけるＧ３ＰＤＨの発現量の値で補正を行った後、さらに「試料無添加」の補正値を１００とした時の「試料添加」の補正値を算出した。ＦＧＦ−７ｍＲＮＡ発現促進率（％）及びＶＥＧＦｍＲＮＡ発現促進率（％）は、下記式に基づいて算出した。
(3) Analysis An amplification curve of a DNA fragment encoding each of FGF-7, VEGF, and G3PDH was prepared from the amount of luminescence of the cyber green dye in each cycle. A calibration curve was prepared from the amplification curve of a dilution series of a single-stranded DNA solution for preparing a calibration curve, with the horizontal axis representing the concentration and the vertical axis representing the number of cycles that maximized the second derivative of the amplification curve. For each expression quantification sample, the number of cycles that maximized the second derivative of the amplification curve was plotted on a calibration curve, and the relative expression level was calculated. The FGF-7 and VEGF expression levels were corrected with the value of G3PDH expression level in the same sample, and then the correction value for “sample addition” when the correction value for “no sample addition” was set to 100 was calculated. . The FGF-7 mRNA expression promotion rate (%) and the VEGF mRNA expression promotion rate (%) were calculated based on the following formulas.
ｍＲＮＡ発現促進率(％)＝Ｂ／Ａ×１００
式中、Ａは「試料無添加時の補正値」を表し、Ｂは「試料添加時の補正値」を表す。
上記試験の結果を表１０に示す。
mRNA expression promotion rate (%) = B / A × 100
In the formula, A represents “correction value when no sample is added”, and B represents “correction value when a sample is added”.
The results of the above test are shown in Table 10.
表１０に示すように、金不換地上部抽出物、ヒメハギ地上部抽出物、小花遠志地上部抽出物及び白眉草全草抽出物は、優れたＦＧＦ−７産生促進作用を有することが確認された。また、金不換地上部抽出物、ヒメハギ地上部抽出物、小花遠志地上部抽出物、白眉草全草抽出物及び仮鷹爪葉部抽出物は、優れたＶＥＧＦ産生促進作用を有することが確認された。 As shown in Table 10, it was confirmed that the gold-unconverted aboveground extract, the ground extract, the above-extracted floret extract, and the whole white blossom grass extract have an excellent FGF-7 production promoting action. In addition, it was confirmed that the gold-unconverted above-ground extract, the ground extract, the above-ground extract of the small flower, the above-mentioned extract of the white blossom grass, and the extract of the falcon nail leaves have an excellent VEGF production promoting action. .
〔配合例１〕
下記組成の養毛ヘアートニックを常法により製造した。
金不換５０容量％エタノール抽出物（製造例１） ０．５ｇ
白眉草８０容量％エタノール抽出物（製造例４） ０．３ｇ
塩酸ピリドキシン ０．１ｇ
レゾルシン ０．０１ｇ
Ｄ−パントテニルアルコール ０．１ｇ
グリチルリチン酸ジカリウム ０．１ｇ
Ｌ−メントール ０．０５ｇ
１，３−ブチレングリコール ４．０ｇ
ニンジンエキス ０．２ｇ
エタノール ２５．０ｇ
香料 適量
精製水 残部（全量を１００ｇとする）
[Formulation Example 1]
A hair nourishing hair tonic having the following composition was produced by a conventional method.
Gold conversion 50 vol% ethanol extract (Production Example 1) 0.5g
White eyebrows 80 vol% ethanol extract (Production Example 4) 0.3g
0.1 g of pyridoxine hydrochloride
Resorcin 0.01g
D-pantothenyl alcohol 0.1g
0.1g dipotassium glycyrrhizinate
L-Menthol 0.05g
1,3-butylene glycol 4.0 g
Carrot extract 0.2g
Ethanol 25.0g
Perfume Appropriate amount Purified water The rest (the total amount is 100 g)
〔配合例２〕
下記組成の養毛ヘアートニックを常法により製造した。
ヒメハギ８０容量％エタノール抽出物（製造例２） ０．４ｇ
鳳凰木５０容量％エタノール抽出物（製造例５） ０．３ｇ
仮鷹爪５０容量％エタノール抽出物（製造例６） ０．３ｇ
酢酸トコフェロール 適量
セファラチン ０．００２ｇ
イソプロピルメチルフェノール ０．１ｇ
ヒアルロン酸ナトリウム ０．１５ｇ
グリセリン １５．０ｇ
エタノール １５．０ｇ
香料 適量
キレート剤（エデト酸ナトリウム） 適量
防腐剤（ヒノキチオール） 適量
可溶化剤（ポリオキシエチレンセチルエーテル） 適量
精製水 残部（全量を１００ｇとする）
[Formulation Example 2]
A hair nourishing hair tonic having the following composition was produced by a conventional method.
80g ethanol volume extract (Production Example 2) 0.4g
Inoki 50% ethanol extract (Production Example 5) 0.3 g
Temporary nail 50% ethanol extract (Production Example 6) 0.3g
Tocopherol acetate appropriate amount Cephalatin 0.002g
Isopropylmethylphenol 0.1g
Sodium hyaluronate 0.15g
Glycerin 15.0g
15.0 g of ethanol
Fragrance Appropriate amount Chelating agent (Sodium edetate) Appropriate amount Preservative (hinokitiol) Appropriate amount Solubilizer (Polyoxyethylene cetyl ether) Appropriate amount Purified water The remainder (100% total)
〔配合例３〕
下記組成の育毛シャンプーを常法により製造した。
小花遠志水抽出物（製造例３） ０．２ｇ
白眉草水抽出物（製造例４） ０．３ｇ
ヤシ油脂肪酸メチルタウリンナトリウム １０．０ｇ
ヤシ油脂肪酸アミドプロピルベタイン １０．０ｇ
ポリオキシエチレンアルキルエーテル硫酸ナトリウム ２０．０ｇ
ヤシ油脂肪酸ジエタノールアミド ４．０ｇ
プロピレングリコール ２．０ｇ
香料 適量
精製水 残部（全量を１００ｇとする）
[Composition Example 3]
A hair growth shampoo having the following composition was produced by a conventional method.
Kobana Enshi Water Extract (Production Example 3) 0.2g
White eyebrows water extract (Production Example 4) 0.3g
Coconut oil fatty acid methyl taurine sodium 10.0g
Coconut oil fatty acid amidopropyl betaine 10.0g
Sodium polyoxyethylene alkyl ether sulfate 20.0g
Coconut oil fatty acid diethanolamide 4.0g
Propylene glycol 2.0g
Perfume Appropriate amount Purified water The rest (the total amount is 100 g)
〔配合例４〕
下記組成の育毛シャンプーを常法により製造した。
金不換水抽出物（製造例１） ０．４ｇ
鳳凰木５０容量％エタノール抽出物（製造例５） ０．３ｇ
仮鷹爪水抽出物（製造例６） ０．３ｇ
ポリオキシエチレンアルキルエーテル硫酸ナトリウム ３０．０ｇ
ヤシ油脂肪酸アミドプロピルベタイン ３０．０ｇ
ヤシ油脂肪酸メチルタウリンナトリウム ２０．０ｇ
ヤシ油ジエタノールアミド ３．０ｇ
ジステアリン酸エチレングリコール ２．０ｇ
香料 適量
防腐剤（パラオキシ安息香酸メチル） ０．１５ｇ
１，３−ブチレングリコール ３．０ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 4]
A hair growth shampoo having the following composition was produced by a conventional method.
Gold invariant water extract (Production Example 1) 0.4 g
Inoki 50% ethanol extract (Production Example 5) 0.3 g
Temporary nail extract (Production Example 6) 0.3g
Sodium polyoxyethylene alkyl ether sulfate 30.0g
Coconut oil fatty acid amidopropyl betaine 30.0g
Palm oil fatty acid methyl taurine sodium 20.0g
Coconut oil diethanolamide 3.0g
2.0g ethylene distearate
Fragrance Appropriate amount Preservative (methyl paraoxybenzoate) 0.15g
1,3-butylene glycol 3.0 g
Purified water remainder (total amount is 100 g)
本発明の毛乳頭細胞増殖促進剤、ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、抗男性ホルモン剤、育毛剤及び頭髪化粧料は、脱毛症等の予防、治療又は改善に大きく貢献できる。 The hair papilla cell proliferation promoter, FGF-7 production promoter, VEGF production promoter, anti-androgen hormone agent, hair restorer and hair cosmetic of the present invention can greatly contribute to the prevention, treatment or improvement of alopecia and the like.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007285821A JP5676837B2 (en) | 2007-11-02 | 2007-11-02 | Hair papilla cell growth promoter, fibroblast growth factor-7 (FGF-7) production promoter, vascular endothelial growth factor (VEGF) production promoter, antiandrogen, hair restorer and hair cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007285821A JP5676837B2 (en) | 2007-11-02 | 2007-11-02 | Hair papilla cell growth promoter, fibroblast growth factor-7 (FGF-7) production promoter, vascular endothelial growth factor (VEGF) production promoter, antiandrogen, hair restorer and hair cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009114082A true JP2009114082A (en) | 2009-05-28 |
| JP5676837B2 JP5676837B2 (en) | 2015-02-25 |
Family
ID=40781639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007285821A Active JP5676837B2 (en) | 2007-11-02 | 2007-11-02 | Hair papilla cell growth promoter, fibroblast growth factor-7 (FGF-7) production promoter, vascular endothelial growth factor (VEGF) production promoter, antiandrogen, hair restorer and hair cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5676837B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012236774A (en) * | 2011-05-09 | 2012-12-06 | Kyoei Kagaku Kogyo Kk | Fibroblast growth factor production promoter, vascular endothelial cell growth factor production promoter, and hair cosmetic |
| CN103251541A (en) * | 2013-05-30 | 2013-08-21 | 云南七丹药业股份有限公司 | Liquid shampoo containing notoginsenoside and preparation method thereof |
| KR20170076429A (en) * | 2015-12-24 | 2017-07-04 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising Polygalasaponin F |
| CN113652426A (en) * | 2021-08-20 | 2021-11-16 | 昆明理工大学 | Panax notoginseng inducible promoter R1 and application thereof |
| CN113884613A (en) * | 2021-08-31 | 2022-01-04 | 贵州医科大学 | Dactylicapnos tomentosa herb pharmacokinetic analysis method |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS643126A (en) * | 1987-06-26 | 1989-01-06 | Bitamin Kenkyusho:Kk | Androgen acceptor bonding inhibitor |
| JPH01316327A (en) * | 1988-04-25 | 1989-12-21 | Ethicon Inc | Wound treatment composition containing growth factor and retinoid |
| JPH0259507A (en) * | 1988-02-25 | 1990-02-28 | Beecham Group Plc | Hair care composition |
| JPH03188013A (en) * | 1989-12-15 | 1991-08-16 | Shiseido Co Ltd | Testosterone-5alpha-reductase inhibitor |
| JPH04342535A (en) * | 1991-07-12 | 1992-11-30 | Rohto Pharmaceut Co Ltd | Testosterone 5alpha-reductase inhibitor |
| JPH0640861A (en) * | 1992-04-23 | 1994-02-15 | Shiseido Co Ltd | Composition for head |
| JPH09208431A (en) * | 1996-02-07 | 1997-08-12 | Yutaka Miyauchi | Hair tonic having promoting action on growth of hair papilla cell |
| JPH1135426A (en) * | 1994-01-25 | 1999-02-09 | Shiseido Co Ltd | Composition for head |
| JP2940964B2 (en) * | 1989-12-15 | 1999-08-25 | 株式会社資生堂 | Testosterone-5α-reductase inhibitor |
| JP2000007534A (en) * | 1998-06-17 | 2000-01-11 | Shiseido Co Ltd | Composition for skin of scalp and hair |
| JP2001131026A (en) * | 1999-11-08 | 2001-05-15 | Shiseido Co Ltd | Cosmetic for scalp and hair |
| JP2003212784A (en) * | 2002-01-11 | 2003-07-30 | Pharmaceutical Industry Technology & Development Center | Antidepressant composition containing polygala plant extract |
| WO2004030683A1 (en) * | 2002-10-01 | 2004-04-15 | Takara Bio Inc. | Remedies |
| JP2005514947A (en) * | 2002-01-25 | 2005-05-26 | エヴォルヴァ・リミテッド | Multi-parameter screening and evolution to multi-functional small molecule producing cells |
| WO2006090613A1 (en) * | 2005-02-22 | 2006-08-31 | Maruzen Pharmaceuticals Co., Ltd. | Hair cosmetic |
| JP2007504240A (en) * | 2003-09-02 | 2007-03-01 | ユニゲン・ファーマシューティカルス・インコーポレーテッド | Formulation of a mixture of free B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairment |
| JP2008105983A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
-
2007
- 2007-11-02 JP JP2007285821A patent/JP5676837B2/en active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS643126A (en) * | 1987-06-26 | 1989-01-06 | Bitamin Kenkyusho:Kk | Androgen acceptor bonding inhibitor |
| JPH0259507A (en) * | 1988-02-25 | 1990-02-28 | Beecham Group Plc | Hair care composition |
| JPH01316327A (en) * | 1988-04-25 | 1989-12-21 | Ethicon Inc | Wound treatment composition containing growth factor and retinoid |
| JP2940964B2 (en) * | 1989-12-15 | 1999-08-25 | 株式会社資生堂 | Testosterone-5α-reductase inhibitor |
| JPH03188013A (en) * | 1989-12-15 | 1991-08-16 | Shiseido Co Ltd | Testosterone-5alpha-reductase inhibitor |
| JPH04342535A (en) * | 1991-07-12 | 1992-11-30 | Rohto Pharmaceut Co Ltd | Testosterone 5alpha-reductase inhibitor |
| JPH0640861A (en) * | 1992-04-23 | 1994-02-15 | Shiseido Co Ltd | Composition for head |
| JPH1135426A (en) * | 1994-01-25 | 1999-02-09 | Shiseido Co Ltd | Composition for head |
| JPH09208431A (en) * | 1996-02-07 | 1997-08-12 | Yutaka Miyauchi | Hair tonic having promoting action on growth of hair papilla cell |
| JP2000007534A (en) * | 1998-06-17 | 2000-01-11 | Shiseido Co Ltd | Composition for skin of scalp and hair |
| JP2001131026A (en) * | 1999-11-08 | 2001-05-15 | Shiseido Co Ltd | Cosmetic for scalp and hair |
| JP2003212784A (en) * | 2002-01-11 | 2003-07-30 | Pharmaceutical Industry Technology & Development Center | Antidepressant composition containing polygala plant extract |
| JP2005514947A (en) * | 2002-01-25 | 2005-05-26 | エヴォルヴァ・リミテッド | Multi-parameter screening and evolution to multi-functional small molecule producing cells |
| WO2004030683A1 (en) * | 2002-10-01 | 2004-04-15 | Takara Bio Inc. | Remedies |
| JP2007504240A (en) * | 2003-09-02 | 2007-03-01 | ユニゲン・ファーマシューティカルス・インコーポレーテッド | Formulation of a mixture of free B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairment |
| WO2006090613A1 (en) * | 2005-02-22 | 2006-08-31 | Maruzen Pharmaceuticals Co., Ltd. | Hair cosmetic |
| JP2008105983A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
Non-Patent Citations (6)
| Title |
|---|
| CSNC200801398010; ＦＲＡＧＲＡＮＣＥ ＪＯＵＲＮＡＬ Ｖｏｌ．３３， Ｎｏ．１２, 20051215, Ｐａｇｅ．１７-２４, フレグランス ジャーナル社 * |
| JPN6012046720; 朝日百科 植物の世界 , 19971001, 第３-３０６頁〜第３-３０８頁, 朝日新聞社 * |
| JPN6012046721; Ｐｏｌｙｇａｌａ ｃｈｉｎｅｎｓｉｓ ｉｎｆｏｒｍａｔｉｏｎ ｆｒｏｍ ＮＰＧＳ／ＳＲＩＮ , 20010424 * |
| JPN6012046722; '中国四川省民間薬の生薬学的研究 （第２報） Ｇｅｒｂｅｒａ属植物由来の兎耳風について' 薬学雑誌 Ｖｏｌ．１１０ Ｎｏ．６, 199006, Ｐａｇｅ．３７４-３８２ * |
| JPN6012046723; ＦＲＡＧＲＡＮＣＥ ＪＯＵＲＮＡＬ Ｖｏｌ．３３， Ｎｏ．１２, 20051215, Ｐａｇｅ．１７-２４, フレグランス ジャーナル社 * |
| JPN6013005475; ＧＵＲＡＶ，Ｓ．Ｓ．: 'Ｆｒｅｅ ｒａｄｉｃａｌ ｓｃａｖｅｎｇｉｎｇ ａｃｔｉｖｉｔｙ ｏｆ Ｐｏｌｙｇａｌａ ｃｈｉｎｅｎｓｉｓ Ｌｉｎｎ' Ｐｈａｒｍａｃｏｌｏｇｙｏｎｌｉｎｅ Ｖｏｌ．２, 20070201, ｐ．２４５-２５３ * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012236774A (en) * | 2011-05-09 | 2012-12-06 | Kyoei Kagaku Kogyo Kk | Fibroblast growth factor production promoter, vascular endothelial cell growth factor production promoter, and hair cosmetic |
| CN103251541A (en) * | 2013-05-30 | 2013-08-21 | 云南七丹药业股份有限公司 | Liquid shampoo containing notoginsenoside and preparation method thereof |
| KR20170076429A (en) * | 2015-12-24 | 2017-07-04 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising Polygalasaponin F |
| KR102503107B1 (en) | 2015-12-24 | 2023-02-22 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising Polygalasaponin F |
| CN113652426A (en) * | 2021-08-20 | 2021-11-16 | 昆明理工大学 | Panax notoginseng inducible promoter R1 and application thereof |
| CN113652426B (en) * | 2021-08-20 | 2023-06-20 | 昆明理工大学 | Pseudo-ginseng inducible promoter R1 and application thereof |
| CN113884613A (en) * | 2021-08-31 | 2022-01-04 | 贵州医科大学 | Dactylicapnos tomentosa herb pharmacokinetic analysis method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5676837B2 (en) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7910557B2 (en) | Hair care product | |
| JP4939766B2 (en) | Basement membrane stabilizer | |
| JP5676837B2 (en) | Hair papilla cell growth promoter, fibroblast growth factor-7 (FGF-7) production promoter, vascular endothelial growth factor (VEGF) production promoter, antiandrogen, hair restorer and hair cosmetics | |
| JP5654214B2 (en) | Hair suppressant and skin cosmetic for hair suppression | |
| JP6485995B2 (en) | Endothelin-1 mRNA expression increase inhibitor, stem cell growth factor mRNA expression increase inhibitor, basic fibroblast growth factor mRNA expression increase inhibitor, and proopiomelanocortin mRNA expression increase inhibitor | |
| JP5224719B2 (en) | Hair papilla cell growth promoter, testosterone 5α-reductase inhibitor, androgen receptor binding inhibitor, vascular endothelial growth factor production promoter, bone morphogenetic protein-2 production promoter, insulin-like growth factor-1 production promoter, hair restorer And hair cosmetics | |
| JP2014185131A (en) | Hair growing agent and hair cosmetic for hair growth | |
| JP2014185130A (en) | Hair cosmetic for hair growth | |
| KR101066797B1 (en) | Hair growth agent composition | |
| JP5889506B2 (en) | Hair papilla cell growth promoter | |
| JP5067916B2 (en) | Skin cosmetics and hair cosmetics | |
| JP5668001B2 (en) | Skin cosmetics and hair cosmetics | |
| JP2011241162A (en) | FGF-7 PRODUCTION PROMOTER, VEGF PRODUCTION PROMOTER, IGF-1 PRODUCTION PROMOTER, HGF PRODUCTION PROMOTER, TESTOSTERONE 5α-REDUCTASE INHIBITOR, AND HAIR TONIC | |
| JP2006347915A (en) | Hair tonic, antiandrogen agent and hair cosmetic | |
| JP5312063B2 (en) | FGF-7 production promoter, VEGF production promoter, IGF-1 production promoter, HGF production promoter, BMP-2 production promoter, FGF-18 production promoter, and type 2 testosterone 5α-reductase production inhibitor | |
| JP4633421B2 (en) | Hair restorer and scalp cosmetic | |
| JP2018193407A (en) | EPIDERMIS HYALURONIC ACID PRODUCTION PROMOTER, GLUTATHIONE PRODUCTION PROMOTER, SERINE PALMITOYLTRANSFERASE mRNA EXPRESSION PROMOTER, DECOMPOSITION ACCELERATOR OF ADVANCED GLYCATION END PRODUCT, CLAUDIN-1 PRODUCTION PROMOTER, OCCLUDIN PRODUCTION PROMOTER, EPIDERMIS TIGHT JUNCTION-CONSTITUTING PROTEIN PRODUCTION PROMOTER IN HUMAN SKIN THREE-DIMENSIONAL MODEL, SKIN BARRIER FUNCTION REDUCTION INHIBITOR, TESTOSTERONE 5α- REDUCTASE ACTIVITY INHIBITOR, AND HAIR PAPILLA CELL PROLIFERATION PROMOTER | |
| JP7220488B2 (en) | Testosterone 5α-reductase activity inhibitor or glutathione production promoter | |
| JP6969042B2 (en) | Claudin-1 production promoter, occludin production promoter, epidermal tight junction constituent protein production promoter in human skin three-dimensional model, and skin barrier function decline inhibitor | |
| JP2009001523A (en) | Antiandrogenic agent, hair grower and hair cosmetic | |
| EP4140490A1 (en) | Composition for amelioration, prevention or treatment of hair loss, comprising catechin 7-o-?-d-apiofuranoside as active ingredient | |
| JP4803698B2 (en) | Anti-aging agent, estrogenic agent, anti-androgen agent, hair restorer, testosterone 5α-reductase inhibitor, skin cosmetic and hair cosmetic | |
| KR20060008662A (en) | Hair growth agent composition | |
| JP2024012179A (en) | Hair cycle regulator expression regulating agent | |
| JP2023149544A (en) | TESTOSTERONE 5α-REDUCTASE ACTIVITY INHIBITORS, ANTI-ANDROGENIC AGENTS, HGF MRNA EXPRESSION PROMOTING AGENTS, HGF PROTEIN PRODUCTION PROMOTING AGENTS AND KAP5.1 MRNA EXPRESSION PROMOTING AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101026 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120905 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130711 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130723 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130906 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141226 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5676837 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |